

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 251/66, 251/70, A61K 31/53, C07D 403/12, 405/12, 409/12		A1	(11) International Publication Number: WO 99/36410 (43) International Publication Date: 22 July 1999 (22.07.99)
(21) International Application Number: PCT/US99/00945		(81) Designated States: CA, GD, HR, ID, IN, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 13 January 1999 (13.01.99)		Published <i>With international search report.</i>	
(30) Priority Data: 09/006,430 13 January 1998 (13.01.98) US			
(71) Applicant: SCRIPTGEN PHARMACEUTICALS, INC. [US/US]; 610 Lincoln Street, Waltham, MA 02154 (US).			
(72) Inventors: ARENAS, Jaime, E.; 26 Ledgelawn Avenue, Lexington, MA 02173 (US). CLOAD, Sharon, T.; 162 Chilton Street, Cambridge, MA 02138 (US). FLEMING, Elizabeth, S.; 30 Shean Road, Belmont, MA 02178 (US). XIANG, Yi, Bin; 821 Main Street, Acton, MA 01720 (US).			
(74) Agents: LUDWIG, S., Peter et al.; Darby & Darby P.C., 805 Third Avenue, New York, NY 10022-7513 (US).			

(54) Title: TRIAZINE ANTIVIRAL COMPOUNDS**(57) Abstract**

The present invention provides pharmaceutical formulations comprising 1,3,5-triazine derivatives. The compounds and formulations of the present invention exhibit a range of activities, including antiviral and antibiotic activities, and the formulations may be used, alone or in combination, as a method of treating a patient in need of antiviral and/or antibiotic therapy. The triazine derivatives of the present invention bind to and inhibit functional nucleic acids, and hence, have broad applicability in the treatment of conditions associated with DNA and RNA viruses.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Hungary	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Ireland	TT	Trinidad and Tobago
BJ	Benin	IE	Iceland	MR	Israel	UA	Ukraine
BR	Brazil	IL	Italy	MW	Mauritania	UG	Uganda
BY	Belarus	IS	Japan	MX	Malawi	US	United States of America
CA	Canada	IT	Kenya	NE	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Kyrgyzstan	NL	Niger	VN	Viet Nam
CG	Congo	KE	Democratic People's Republic of Korea	NO	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Republic of Korea	NZ	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Republic of Korce	PL	New Zealand		
CM	Cameroon	KR	Kazakhstan	PT	Poland		
CN	China	KZ	Saint Lucia	RO	Portugal		
CU	Cuba	LC	Liechtenstein	RU	Romania		
CZ	Czech Republic	LI	Sri Lanka	SD	Russian Federation		
DE	Germany	LK	Liberia	SE	Sudan		
DK	Denmark	LR		SG	Sweden		
EE	Estonia				Singapore		

- 1 -

5

TRIAZINE ANTIVIRAL COMPOUNDS

Field of the Invention

10 This invention pertains to the interaction between nucleic acids and 1,3,5-triazine derivatives, their use as inhibitors of the replication of the Hepatitis B virus (HBV), and their use in the treatment of viral hepatitis caused by HBV.

Background of the Invention

15 There is a great medical need for novel therapeutic drugs to treat viral infections. Approximately 300,000 Americans become infected annually with hepatitis B virus (HBV). Currently available drugs for the treatment of HBV have limited efficacy and have not exhibited lasting effects, such that virus titres rapidly increase following the termination of drug treatment. In addition, some classes of 20 drugs, such as nucleoside analogs that inhibit the viral polymerase, often become ineffective due to the rapid appearance of resistant viral strains. For these reasons, it has become apparent that combination therapies utilizing multiple drugs that function by different mechanisms are likely to be more successful in the treatment of viral infections.

25 Small molecules can bind RNA with high affinity and specificity and can block essential functions of the bound RNA. Examples of such molecules are

- 2 -

5 antibiotics such as erythromycin and aminoglycosides. The first suggestion that some antibiotic translation inhibitors interact specifically with RNA came from the genetic mapping of resistance to kanamycin and gentamicin to the methylation of 16S RNA (Thompson et al., *Mol. Gen. Genet.* 201:168, 1985). Erythromycin binds to bacterial RNA and releases peptidyl-tRNA and mRNA (Menninger et al.,
10 *Mol. Gen. Genet.* 243:225, 1994). 2-DOS-containing aminoglycosides bind specifically to the structures of HIV RNA known as the RRE, block binding of the HIV Rev protein to this RNA, and thereby inhibit HIV replication in tissue culture cells (Zapp et al., *Cell* 74:969, 1993). In addition, although aminoglycosides have long been developed as translation inhibitors, they were only recently shown to bind
15 to rRNA in the absence of proteins (Purohit and Stern, *Nature* 370:659, 1994).
Hygromycin B inhibits coronaviral RNA synthesis and is thought to do so by binding to the viral RNA and blocking specifically the translation of viral RNA (Macintyre et al., *Antimicrob. Agents Chemother.* 35:2630, 1991). Therefore, compounds that bind to functionally important regions of nucleic acids of viruses
20 and microorganisms may be useful as inhibitors of replication or other functions, *i.e.*, as antiviral agents and antibiotics.

The present invention pertains specifically to a novel class of drugs comprising RNA ligands that alter the function(s) of their target RNAs. This class of compounds comprises substituted 1,3,5-triazine derivatives that specifically recognize an essential and multifunctional RNA structure of the HBV pregenomic RNA known as the encapsidation signal (ϵ RNA). It has been unexpectedly found that this class of compounds can function as inhibitors of HBV replication. ϵ RNA, shown in Figure 2A, consists of a short sequence that folds into a stem-loop structure interrupted by a 6 nucleotide bulge. ϵ RNA, which is contained within the open reading frame encoding the HBV precore protein, is also required for various steps of the HBV viral replication cycle, including encapsidation of the pregenome into viral particles and initiation of minus strand DNA synthesis. ϵ RNA may also play a role in folding and activation of the HBV-encoded polymerase.
25
30

- 3 -

5 Derivatives of melamine, 1,3,5-triazine-2,4,6-triamine, have been reported in the literature as suitable for various uses. For example, 2,4,6-tris(dimethylamino)-1,3,5-triazine is an antitumor agent known as Altretamine®, used in the treatment of ovarian cancer (*Cancer* **71**; 4 Suppl.: 1559, 1993). Similarly, Larvadex (N-cyclopropyl-1,3,5-triazine-2,4,6-triamine) has been used as
10 an additive to animal feed stock to control house fly infestation in poultry houses (*Poult. Sci.* **62**(12): 2371, 1983).

15 Further, Patel *et al.* (*J. Inst. Chemists (India)*, **57**, 1985) report a number of derivatives of 2-aryl amino-4-(4-methoxy anilino)-6-(4-chlorophenyl/phenyl hydrazido)-1,3,5-triazine having anti-bacterial activity, without data in support of this conclusion and absent any suggestion that the compounds could be used as antiviral agents.

20 U.S. Patent No. 5,225,405 to Paramelle *et al.* refers to 4,6-bis-allylamino-1,3,5-triazin-2-yl derivatives which reverse acquired resistance to anti-cancer and anti-malarial agents. Paramelle *et al.* state that the disclosed triazine derivatives, when administered at the same time with a cytotoxic agent, reduce or completely suppress multidrug resistance. The triazine compounds presumably act by inhibiting the action of an inducible membrane protein that normally functions to increase the efflux of the cytotoxic agent, thereby reducing its intracellular concentration. Paramelle *et al.* are silent as to the use of the triazine derivatives as
25 antiviral agents.

30 U.S. Patent No. 4,508,898 to Ogilvie relates to nucleoside analogs that have a 1,3,5-triazine moiety, wherein the analog compounds exhibited antiviral activity. The compounds of Ogilvie, however, do not comprise 2,4,6-triamino-1,3,5-triazine derivatives, but rather, are N-substituted purine and pyrimidine compounds.

European Patent Application No. 172 608 to Kim *et al.* relates to 1,3,5-triazine derivatives that exhibit anti-ulcer, anti-inflammatory and anti-

- 4 -

5 depressant activities. However, Kim *et al.* fail to suggest that the disclosed triazine derivatives can be used as antiviral agents.

10 Golankiewicz, *et al.* (*J. Med. Chem.* **38**: 3558, 1995) report the isolation of several 1,3,5-triazine derivatives having antiviral activity. However, the derivatives were limited to imidazo-[1,5- α]-1,3,5-triazine derivatives, with special emphasis on thio- and benzyl-substituted derivatives.

15 Kreutzberger *et al.* (*Arzneim.-Forsch./Drug. Res.* **36** (I)(4): 626, 1986) relates to aliphatically substituted chlorodihexylamino-1,3,5-triazines having antiviral activity. However, these compounds are structurally different from the compounds of the present invention.

20 WO 97/20825 discloses the isolation of various 1,3,5-triazine derivatives structurally distinct from those of the present invention. There is no suggestion that the triazine derivatives can be used as antiviral agents, but rather, that the compounds have utility as herbicides, insecticides, miticides, and bactericides.

25 U.S. Patent No. 4,254,122 to Brown relates to 6-acylaminotetrahydro-1,3,5-triazine-2,4-dione derivatives that exhibit analgesic activities. The disclosed uses of the compound include their use as antiinflammatory agents and as inhibitors of prostaglandin synthetase.

30 Further, European Patent Application No. 795 549 to Gluzman *et al.* refers to bis-aryloxy(amino)-triazinyl-oxy(amino)aryl derivatives as antiviral agents. However, unlike the compounds of the present invention, the compounds of Gluzman *et al.* are dimers, linked by bicyclic or heterocyclic substituted moieties, and Gluzman *et al.* fails to suggest the use of the monomers as therapeutic compounds and/or compositions.

35 Thus, there is a need in the art for the identification of compounds that bind to functional viral nucleic acids, thereby inhibiting viral replication, and for specific antiviral agents that inhibit the replication of Hepatitis B virus. Such antiviral agents would be useful in the treatment of viral hepatitis caused by HBV.

- 5 -


5

Summary of the Invention

The present invention provides methods for inhibiting viral and/or microbial replication, preventing or treating viral and/or microbial infection, and pharmaceutical formulations for use in such methods comprising a compound of the formulae IA

10


15



or IB

20

25



30

wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, non-aromatic heterocyclic, fused or polycyclic ring, and aryloxy;

wherein said alkyl, alkenyl or alkynyl is optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy, amino,

- 6 -

5 carbonyl, carboxyl, ester, amide, primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl, cycloalkenyl or alkenyl; and

wherein said aryl, aryloxy, heteroaryl, non-aromatic heterocyclic, or fused or polycyclic ring is optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl, carboxyl, ester, amide, primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl, cycloalkenyl or alkynyl;

10 or wherein R¹ and R² together, R³ and R⁴ together, or R⁵ and R⁶ together, optionally form a cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, heteroaryl, or fused or polycyclic ring, said cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, heteroaryl, or fused or polycyclic ring optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl, carboxyl, ester, amide, primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl, cycloalkenyl and alkynyl;

15 or wherein R⁷ and R⁸ together optionally form a cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, or fused or polycyclic ring wherein said cycloalkyl, cycloalkenyl, non-aromatic heterocyclic and fused or polycyclic ring are optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl, carboxyl, ester, amide, primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl, cycloalkenyl and alkynyl, with the proviso that when R⁷ and R⁸ together form a fused or polycyclic ring, the moiety of the fused or polycyclic ring that binds with N is non-aromatic;

20 and pharmaceutically acceptable salts thereof;

and a pharmaceutically acceptable carrier or diluent.

Further, it is an object of the present invention to provide antiviral and antibiotic formulations comprising one or more compounds represented by the

- 7 -

5 formulae set forth above and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier or diluent, and methods of administering such formulations to a patient in need of antiviral and/or antibacterial therapy. It is also an object of the present invention to provide a method of detecting a target nucleic acid by contacting the target nucleic acid with at least one compound of the
10 formulae set forth above and pharmaceutically acceptable salts thereof, and monitoring an interaction between the target nucleic acid and the at least one compound of the formulae set forth above.

Brief Description of the Drawings

15 Figures 1A-1K are graphic illustrations of preferred 1,3,5-triazine compounds of the present invention.

Figure 2A is a schematic illustration of the HBV pregenomic sequence that corresponds to the encapsidation signal (ϵ RNA).

20 Figure 2B is a schematic illustration of the target RNAs used in the method of the present invention.

Figure 3 is a graphical illustration of the reduction in virus production when compound 5 and the antiviral drug 2'-deoxy-3'-thiacytidine were tested at various concentrations alone and in combinations in an antiviral assay using 2.2.15 cells producing HBV.

25 Figures 4A, 4B, and 4C are graphical illustrations of the percentage viral reduction when compounds 5 and antiviral drug 2'-deoxy-3'-thiacytidine were tested in combination, with molar ratios of 1:15, 1:5, and 1:1.5, respectively.

30 Figures 5A and 5B are photographic and schematic representations, respectively, of the results of the reaction of rRNA, ϵ RNA, RNase, and compound 5 at concentrations ranging from 0 and 200 μ M.

Figures 6A and 6B are graphical and schematic illustrations, respectively, of the change in the melting temperature (tm) of ϵ RNA in the presence and absence of compound 6.

- 8 -

5

Detailed Description of the Invention

All patent applications, patents, and literature references cited in this specification are hereby incorporated by reference in their entirety. In case of conflict, the present description, including definitions, will prevail.

10

Definitions

As used herein, the term "ligand" refers to an agent that binds a target RNA. The agent may bind the target RNA when the target RNA is in a native or alternative conformation, or when it is partially or totally unfolded or denatured. According to the present invention, a ligand can be an agent that binds anywhere on the target RNA. Therefore, the ligands of the present invention encompass agents that in and of themselves may have no apparent biological function beyond their ability to bind to the target RNA.

15

As used herein, the term "test ligand" refers to an agent, comprising a compound, molecule, or complex, which is being tested for its ability to bind to a target RNA.

20

As used herein, the term "target RNA" refers to a RNA sequence for which identification of a ligand or binding partner is desired. Target RNAs include without limitation sequences known or believed to be involved in the etiology of a given disease, condition or pathophysiological state, or in the regulation of physiological function. Target RNAs may be derived from any living organism, such as a vertebrate, particularly a mammal and even more particularly a human, or from a virus, bacterium, fungus, protozoan, parasite or bacteriophage. Target RNAs may comprise wild type sequences, or, alternatively, mutant or variant sequences, including those with altered stability, activity, or other variant properties, or hybrid sequences to which heterologous sequences have been added. Furthermore, target RNA as used herein includes RNA that has been chemically

25

30

- 9 -

5 modified, such as, for example, by conjugation of biotin, peptides, modified bases, fluorescent molecules, and the like.

Target RNA sequences for use in the present invention are typically between about 5 and about 500 nt, preferably between about 30 and about 100 nt, and most preferably about 50 nt. Target RNAs may be isolated from native 10 sources, or, more preferably, are synthesized *in vitro* using conventional polymerase-directed cell-free systems such as those employing T7 RNA polymerase. In a preferred embodiment, the target RNA is HBV ϵ RNA. Figure 2A shows the actual portion of the HBV pregenomic sequence that corresponds to the encapsidation signal (ϵ RNA). Figure 2B shows the ϵ RNA sequence used as 15 target RNA in the method of the present invention, and the RRE RNA target used for specificity tests. The target RNA was prepared by *in vitro* transcription of a linearized plasmid containing the cloned target sequence, with bacteriophage SP6 RNA polymerase in the presence of α P³²-UTP to obtain radiolabeled target RNA using methods known to those of ordinary skill in the art.

20 As used herein, the term "treatment" with regard to a viral or microbial infection includes preventing, retarding, and/or reducing a disease, pathological condition or one or more symptoms thereof, in vertebrates, e.g., birds, and mammals, particularly humans. In the case of HBV, the altering or inhibiting 25 any of the following processes can be considered very useful for the treatment of infection mediated by HBV. They are:

1. Symptoms associated with acute hepatitis, including the onset of the prodromal phase, which is accompanied by anorexia, malaise, nausea and vomiting, and often fever, and which is followed in the icteric phase by the occurrence of urticarial eruptions, arthralgias and jaundice;
2. Elevations in serum aminotransferase and urinary bile levels prior to and during the onset of maximal jaundice;
3. Low-normal white blood cell counts, and appearance on blood smears of atypical lymphocytes; or

- 10 -

- 5 4. Symptoms associated with chronic hepatitis infection, including viremia, seroconversion, liver cancer, and cirrhosis.

10 According to the present invention, treatment constitutes any improvement in one or more clinical or histological symptoms or diagnostic markers observed by the attending physician or determined by quantitative or semiquantitative techniques. Non-limiting examples of appropriate techniques include analysis of blood and urine.

15 As used herein, "inhibition of replication" refers to any detectable reduction in replication or growth of virus, bacteria or fungi, e.g. between about 1% and about 100% reduction, preferably between about 5% and about 100% reduction, and more preferably between about 10% and about 100% reduction. The skilled artisan will appreciate that any reduction in viral replication, bacterial or fungal growth is significant where it is approximately equal to or greater than that which is observed for known inhibitors of viral replication, bacterial or fungal growth.

20 As used herein, the terms "antibiotic", "antibacterial" and "antifungal" refer to any compound that inhibits growth of or destroys microorganisms, bacteria, or fungi.

25 As used herein, the term "aryl" means an aromatic carbocyclic ring system having a single radical containing about 6 to about 10 carbon atoms. An aryl group may be a fused or polycyclic ring system. Exemplary aryl groups include phenyl or naphthyl.

30 As used herein, the term "aryloxy" means an O-aryl group. An aryloxy group is optionally substituted on the aryl moiety of the aryloxy. Suitable substituents include halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl, carboxyl, ester, amide, primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl, cycloalkenyl and alkynyl.


- 11 -

5 As used herein, the term "alkyl" means a straight or branched
saturated hydrocarbon group. Preferred alkyl groups include those having from 1-
12 carbon atoms.

10 As used herein, the term "cycloalkyl" means a non-aromatic
monocyclic or fused or polycyclic ring system of about 3 to about 10 ring carbon
atoms. Optionally one or more of the ring carbon atoms of the cycloalkyl may be
replaced by a heteroatom, such as nitrogen, oxygen or sulfur. Exemplary
cycloalkyl groups include cyclohexyl.

15 As used herein, the term "cycloalkenyl" means a non-aromatic
monocyclic or fused or polycyclic ring system containing a carbon-carbon double
bond and having about 3 to about 10 ring carbon atoms. Optionally one or more of
the ring carbon atoms of the cycloalkyl may be replaced by a heteroatom, such as
nitrogen, oxygen or sulfur.

20 As used herein, the term "carbonyl" or "carbonyl moiety" refers to
any chemical moiety comprising a carbonyl functional group, *e.g.*, a ketone,
aldehyde, carboxylic acid, acid halide, amide, peptide, anhydride and ester. As
used herein, when a ring structure is described as substituted with a carbonyl group,
the ring carbon atom is replaced by the group




25 As used herein, the term "heteroatom" includes nitrogen, oxygen and
sulfur, as well as any atom other than a carbon.

As used herein, the term "ring system" refers to an aromatic or non-
aromatic
carbocyclic compound, in which one or more of the ring carbon atoms may be
replaced by

- 12 -


5 a heteroatom, such as nitrogen, oxygen or sulfur. The ring system may be optionally substituted by one or more halogens, C₁ to C₁₂ alkyl, aryl, vinyl, alkyl(aryl), vinyl(aryl) and nitro groups.

10 As used herein, the term "fused ring system" refers to ring systems wherein at least two adjacent carbon centers join one or more cyclic structures. A fused ring system as used herein may be aromatic or non-aromatic, or may be composed of separate aromatic and non-aromatic moieties. Exemplary carbocyclic fused ring systems are represented by the formulas:



15

Exemplary fused ring systems in which one or more of the ring carbon atoms is replaced by a heteroatom include the following:




20

- 13 -

5


As used herein, the term "polycyclic ring system" refers to ring systems having two or more cyclic compounds bonded in tandem. A polycyclic ring system as used herein may be aromatic or non-aromatic, or may be composed of separate aromatic and non-aromatic moieties. An exemplary carbocyclic polycyclic ring system is represented by the formula



10

An exemplary polycyclic ring system in which one or more of the ring carbon atoms is replaced by a heteroatom include the following:

15



20

Additionally, fused or polycyclic ring systems may optionally be substituted by one or more halogens, C₁ to C₁₂ alkyl, aryl, vinyl, alkyl(aryl), vinyl(aryl) and nitro groups.

25

As used herein, the term "heteroaryl" means an about 5 to 10-membered aromatic monocyclic or fused or polycyclic ring system having a single radical in which one or more of the carbon atoms in the ring system is other than carbon, for example, nitrogen, oxygen or sulfur. An exemplary heteroaryl group is pyridine. An exemplary fused or polycyclic heteroaryl group is indole.

- 14 -

5 As used herein, the term "heterocyclyl" or "heterocyclic" means an aromatic or non-aromatic about 5 to about 10-membered monocyclic or fused or polycyclic ring system in which one or more of the carbon atoms in the ring system is other than carbon, for example, nitrogen, oxygen or sulfur. A heterocyclyl group may be a fused or polycyclic ring system. Exemplary heterocyclyl groups
10 include piperidine, morpholino, and azepanyl.

As used herein, the term "primary, secondary, or tertiary amine" refers to amine compounds having one, two, or three functional groups, respectively. Suitable functional groups include halogens, amines, C₁ to C₁₂ alkyl groups, aryl, vinyl, alkyl(aryl), vinyl(aryl) and nitro groups.

15 As used herein, the term "amide" refers to groups having the amide functional group -C(O)NH-, wherein alkyl, alkenyl or alkynyl groups may be bonded to the C or N atom of the amide group.


20 As used herein, the term "high affinity" refers to a compound that binds tightly to its target. Preferred compounds of the present invention will exhibit an IC₅₀ at or below 50 μM, preferably at or below 10 μM, and more preferably at or below 1 μM.

25 As used herein, the term "specificity" refers to a compound having either high or low affinity for its target. A highly specific compound will be unaffected by competitor RNA and will not have an effect on a heterologous assay using a different target, independent of the compound's affinity. In a preferred embodiment, compounds of the present invention will exhibit no activity or at least a 5-fold higher IC₅₀ value in a heterologous assay than in a specific assay.

30 The present invention provides methods for inhibiting the replication of viruses and microorganisms and for preventing or treating viral or microbial infection, which comprise administering 1,3,5-triazine compounds and pharmaceutically acceptable salts thereof. The compounds bind Hepatitis B virus (HBV) εRNA with high affinity and specificity, and thereby alter its function. The


- 15 -

5 formulations of the invention comprise triazine derivatives represented by the
formulae IA



or IB

10



15

wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, non-aromatic heterocyclic, fused or polycyclic ring and aryloxy;

20

wherein said alkyl, alkenyl or alkynyl is optionally

substituted with one or more substituents selected from the group consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl, carboxyl, ester, amide, primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl, cycloalkenyl or alkynyl; and

25

- 16 -

5 wherein said aryl, aryloxy, heteroaryl, non-aromatic
heterocyclic or fused or polycyclic ring is optionally substituted by one or more
substituents selected from the group consisting of halogen, hydroxy, alkyl, nitro,
trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl, carboxyl, ester, amide,
primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl, cycloalkenyl or
10 alkynyl;

15 or wherein R¹ and R² together, R³ and R⁴ together, or R⁵ and R⁶
together, optionally form a cycloalkyl, cycloalkenyl, non-aromatic heterocyclic,
heteroaryl, or fused or polycyclic ring, said cycloalkyl, cycloalkenyl, non-aromatic
heterocyclic, heteroaryl, or fused or polycyclic ring optionally substituted with one
15 or more substituents selected from the group consisting of halogen, hydroxy, alkyl,
nitro, trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl, carboxyl, ester,
amide, primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl,
cycloalkenyl and alkynyl;

20 or wherein R⁷ and R⁸ together optionally form a cycloalkyl,
cycloalkenyl, non-aromatic heterocyclic or fused or polycyclic ring, wherein said
cycloalkyl, cycloalkenyl and non-aromatic heterocyclic or fused or polycyclic ring
are optionally substituted with one or more substituents selected from the group
consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy,
amino, carbonyl, carboxyl, ester, amide, primary, secondary or tertiary amines,
25 cyano, cycloalkyl, alkenyl, cycloalkenyl and alkynyl, with the proviso that when R⁷
and R⁸ together form a fused or polycyclic ring, the moiety of the fused or
polycyclic ring that binds with N is non-aromatic;


30 and pharmaceutically acceptable salts thereof;
 and a pharmaceutically acceptable carrier or diluent.

In one embodiment, the invention is directed to compounds of
formula IB wherein one or R¹ and R² is an optionally substituted aryl. In another
embodiment, the invention is directed to compounds of formula IB wherein one of


- 17 -

5 R⁷ or R⁸ is an optionally substituted aryl
compounds of the invention include:

Non-limiting examples of the




II




III

- 18 -

5



IV




V

10


- 19 -

5



VI

10




VII

15

The following is a chemical process for the efficient production of triazines of the formula IA:

20




or IB

- 20 -

5

10

15



Commercially

available cyanuric chloride (IX) is first reacted with two equivalents of a reagent chosen from a group consisting of a primary amine and a secondary amine, to afford a singly substituted triazine of the formula (X).




Fig. IX

Fig. X

- 21 -

- 5 The 2-amino 4,6 di chloro-1,3,5 triazine of the formula (X) is then reacted with two equivalents of a reagent chosen from a group consisting of a primary amine and secondary amine to afford a disubstituted triazine of the formula (XI)




Fig. X

Fig. XI

- 10 The 2,4-diamino-6-chloro-1,3,5 triazine of the formula (XI) can then be reacted with two equivalents of a reagent chosen from a group consisting of a primary amine, secondary amine, and hydrazine. In the case of a primary and secondary amine, the reaction affords a trisubstituted triazine of the formula (XII).




Fig. XI

Fig. XII

In the case of hydrazine, condensation reaction forms compound (XIII).

- 22 -




Fig. XI

Fig. XIII

5

Compound (XII) can then be further reacted with a reagent chosen from a group consisting of aldehydes and ketones to afford 2,4,6- substituted-1,3,5-triazines of the formula (XIV).




Fig. XIII

Fig. XIV

10

DDetailed Description of the Preferred Embodiments

The following is a chemical process for the efficient production of triazine derivatives:

Example 1: 2-fluorobenzaldehyde N-[4-(benzylamino)-6-(tert-butylamino)-1,3,5-triazin-2-yl]hydrazone (compound 93).

15


- 23 -

5

10

15

20




- 24 -

5 Step 1:

To a stirred solution of cyanuric chloride in DME at -30 °C was added a solution of 2 equivalents of benzylamine in water in dropwise fashion. The mixture was then stirred for 3 hrs. at the reduced temperature, after which time the mixture was warmed to room temperature and washed sequentially with saturated sodium bicarbonate and water, dried over magnesium sulfate, and reduced in vacuo.

10 The product was used in the next step without purification.




15

- 25 -

5 Step 2:

To a stirred solution of the product of step 1 in dichloromethane at room temperature was added 2 equivalents of tert-butyl amine in dropwise fashion. The solution was stirred for 12 hrs., after which time the mixture was then washed sequentially with 0.1 M hydrochloric acid, water, and saturated brine, dried over sodium sulfate, reduced in vacuo and recrystallized from hexane:ethyl acetate (4:1) to afford the starting material of step 2.

15




- 26 -

5

Step 3:

10

To a solution of the product of step 2 in dichloromethane was added 2 equivalents of hydrazine in water in dropwise fashion. The solution was then heated to 60°C for a period of 12 hrs., after which time the mixture was cooled to room temperature, washed sequentially with brine and water, dried over sodium sulfate and reduced in vacuo to a residue which was then recrystallized from hexane:ethyl acetate (4:1) to afford the starting material of step 4.




15

Step 4:

To a stirred solution of the product of step 3 in toluene in a round bottom flask was added one equivalent of 2-fluorobenzaldehyde. The flask was then fitted with a Dean Stark trap and refluxed to azeotropically remove water.

- 27 -

5 After which time the removal of water was complete, the solution was cooled to room temperature and the solvent was removed in vacuo. The residue was then recrystallized from hexane:ethyl acetate (5:1) to afford compound 93.



10


- 28 -

5 Example 2: 2-hydroxybenzaldehyde N-[4-(benzylamino)-6-(diethylamino)-1,3,5-triazin-2-yl]hydrazone (compound 155).

Step 1:

To a stirred solution of cyanuric chloride in DME at -30 °C was
10 added a solution of 2 equivalents of benzylamine in water in dropwise fashion. The mixture was then stirred for 3 hrs. at the reduced temperature, after which time the mixture was warmed to room temperature and washed sequentially with saturated sodium bicarbonate and water, dried over magnesium sulfate and reduced in vacuo.
The product was used in the next step without purification.

15




Step 2:

25 To a stirred solution of the product of step 1 in dichloromethane at room temperature was added 2 equivalents of diethyl amine in dropwise fashion. The solution was stirred for 12 hrs., after which time the mixture was then washed

- 29 -

5 sequentially with 0.1 M hydrochloric acid, water and saturated brine, dried over sodium sulfate, reduced in vacuo and recrystallized from hexane:ethyl acetate (4:1) to afford the starting material of step 3.


10



- 30 -

5 Step 3:

To a solution of the product of step 2 in dichloromethane was added 2 equivalents of hydrazine in water in dropwise fashion. The solution was then heated to 60°C for a period of 12 hrs., after which time the mixture was cooled to room temperature, washed sequentially with brine and water, dried over sodium sulfate and reduced in vacuo to a residue which was then recrystallized from hexane:ethyl acetate (4:1) to afford the starting material of Step 4.




15 Step 4:

To a stirred solution of the product of step 3 in toluene in a round bottom flask was added one equivalent of salicylaldehyde. The flask was then fitted with a Dean Stark trap and refluxed to azeotropically remove water. After

- 31 -

5 which time the removal of water was complete, the solution was cooled to room temperature and the solvent was removed in vacuo.




10

The residue was then recrystallized from hexane:ethyl acetate (5:1) to afford compound 155:

15

- 32 -

5



Determination of Antiviral or Antimicrobial Activity

In Vitro Assay

One assay used in determining the activity of the compounds of the
present invention is disclosed in copending U.S. Patent Application Serial No.
10 08/709,342, filed September 6, 1996, the disclosure of which is hereby
incorporated herein by reference in its entirety. The assay detects the interaction
between target RNA molecule and a test ligand by measuring the ligand's ability to
inhibit hybridization between the RNA and a specific complementary
15 oligonucleotide. In one embodiment, the target RNA is radiolabelled and the
oligonucleotide is labeled with biotin; in this case, the extent of hybridization is
determined by measuring the amount of radiolabeled RNA detected with a
streptavidin/biotin-based capture system.

- 33 -

5 Ligands that exhibit inhibitory activity in a primary *in vitro* assay are then titrated and tested in secondary assays to eliminate false positives. Concentrations of test compounds of between about 0.1 μ M and about 200 μ M are assayed for inhibition using radiolabeled ϵ RNA in the absence or presence of a large excess of an unlabeled non-specific RNA competitor (such as, *e.g.*, ribosomal RNA, rRNA). Compounds that bind ϵ RNA non-specifically are competitively displaced by the rRNA, resulting in reduced or no inhibition of hybridization between the radiolabeled ϵ RNA and the biotinylated oligonucleotide. Conversely, the inhibitory activity of compounds that specifically bind ϵ RNA is not affected by the presence of the competitor rRNA.

10 Specificity is further tested in a third assay in which the radiolabeled RNA is the HIV derived RRE RNA and the biotinylated oligonucleotide is complementary to RRE. Compounds with high specific activity for ϵ RNA are not expected to be inhibitory in the RRE RNA based assay. The specificity of the ligand for ϵ RNA is expressed as the ratio between the IC₅₀ value obtained with the specific target RNA and the IC₅₀ value obtained with a heterologous target (RRE RNA), both in the presence of competitor RNA.

15 The substituted 2,4,6-triamino-1,3,5-triazine derivatives of the present invention preferably exhibit IC₅₀ values for their interaction with ϵ RNA at or below 300 μ M, more preferably at or below 50 μ M, and most preferably at or below 5 μ M, in the presence of an excess of non-specific competitor rRNA.

- 34 -

5

Bioassay

10

Ligands that exhibit high affinity and specificity for cRNA as determined above are tested for their ability to inhibit HBV replication. Several cell lines and cell culture assays have been developed to identify potential therapeutics effective against chronic HBV infection. One of these cell lines, 2.2.15, has been used in a standardized assay that has repeatedly proven to be an accurate model of chronic cellular HBV replication and a predictive model of antiviral response for chronic hepadnaviral infection *in vivo*. 2.2.15 cells contain copies of the complete HBV genome integrated into the cell's genome, and 2.2.15 cells are not susceptible to infection by HBV. (Sells, M. A. *et al.*, J. Virol. **62** (8): 2836-2844 (1988)).

15

These cells express HBV genes producing complete HBV particles capable of infecting chimpanzees (Acs, G. *et al.*, Proc. Natl. Acad. Sci. USA **84** (13): 4641-4644 (1987)). Briefly, 2.2.15 cells are cultured and pretreated with a test compound for about 9 days, at which point the media are harvested and subjected to dot-blot hybridization to detect HBV virion DNA.

20

Further, the antiviral effect of any compound must be measured against its toxicity. Cytotoxicity is measured by the neutral red uptake method using the same cells used for antiviral activity.

25

It will be understood that the skilled artisan can employ any assay suitable for assessing the inhibitory potency of a compound to practice the present invention without undue experimentation. See, e.g., J. Sambrook and T. Maniatis, "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor Laboratories

- 35 -

5 Press, Cold Spring Harbor, NY (1989), "Current Protocols in Molecular Biology",
Ed. F.M Ausubel, *et al.*, J. Wiley & Sons, Inc. 1997, D. Leland, "Clinical
Virology", W.B. Saunders Co., 1996, and "Cells: A Laboratory Manual", Ed.
D.L. Spector, *et al.* Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
New York, 1997.

10 The compounds of the present invention are believed to inhibit viral
or microbial replication by binding to functionally important viral or microbial
nucleic acids. The nucleic acids may be RNA or DNA, may form part of the
genome of the virus or microorganism or an intermediate thereof, or may represent
expressed mRNA species or any other functional nucleic acid unique to the
replication or function of the virus or microorganism.

15 Compounds of the present invention inhibit hybridization of the
oligonucleotide probe in the assay described in copending application U.S. Patent
Application Serial No. 08/709,342, filed September 6, 1996. This indicates that the
compounds interact with the RNA target by stabilizing the RNA structure, thereby
inhibiting the formation of hybrids between the RNA target and the complementary
20 oligonucleotide present in the assay.

Supplementary evidence in support of the contention that triazine
compounds interact with the RNA target came from the observation that compound
5 protects specific positions of RNA from digestion with RNases. RNase protection
25 was assessed by incubating an end-labeled RNA with the amount of RNase needed
to yield a ladder representing single cut events at each possible cleavage site in the

- 36 -

5 RNA structure (based upon a gel electrophoresis analysis). The presence of a ligand bound to the RNA renders the binding site inaccessible to the RNases and therefore, the binding site will be shown by the disappearance or weakening of specific bands in the digestion pattern (Figure 5).

10 Further, the RNA binding ability of the triazine compounds was demonstrated by preparing an RNA target containing only the bulge region of εRNA. The melting temperature of the RNA was determined by monitoring the change in optical density at 260 nm with increasing temperature. Upon addition of 10 μM of triazine compound, the melting temperature was shifted, which indicates that the RNA structure is stabilized by the ligand (Figure 6).

15 Thus, these experiments demonstrate that the triazine compounds interact with the bulge region of εRNA by nucleic acid binding.

The methods and formulations of the invention can be used to inhibit replication and/or prevent or treat infection caused by: hepatitis B virus, hepatitis C virus, herpes simplex virus, types 1 and 2, varicella-zoster, cytomegalovirus, 20 Epstein-Barr virus, polyomavirus, papillomavirus, parvovirus, vaccinia virus, molluscum contagiosum, Marburg and Ebola viruses, influenza A and B, measles, mumps, respiratory syncytial virus, poliovirus, coxsackie virus A and B, rhinovirus, rotavirus, human immunodeficiency virus, types 1 and 2, rabies, rubella, and equine encephalitis. DNA and RNA viruses encompassed by the invention, include, without limitation, viruses belonging to the viral families 25 adenoviridae, hepadnaviridae, herpesviridae, papovaviridae, parvoviridae,

- 37 -

5 poxviridae, arenaviridae, bunyaviridae, flaviviridae, orthomyxoviridae,
paramyxoviridae, picornaviridae, reoviridae, retroviridae and rhabdoviridae.

Accordingly, compounds and formulations of the present invention
can be used in the prevention and treatment of viral hepatitis caused by HBV, as
well as in the prevention and treatment of disease conditions associated with other
10 DNA and RNA viruses. Such conditions include, but are not limited to: upper and
lower respiratory tract infections, ocular infections, gastroenteritis, cystidis, and
complications arising in transplant recipients, each of which is associated with
adenoviruses; treatment of immunocompromised individuals, wherein a
compromised immune system is associated with cytomegalovirus; infectious
15 mononucleosis, associated with Epstein-Barr virus; chickenpox and shingles, which
are associated with varicella-zoster; oral, genital and skin lesions, as well as various
dermatological anomalies associated with herpesvirus, papillomavirus and
polyomavirus; smallpox, as well as complications arising from smallpox
vaccinations, including allergic rash, progressive vaccinia and postvaccinal
20 encephalitis, each of which being associated with variola, molluscum and
contagiosum; hemorrhagic fever and aseptic meningitis, which are associated with
lassa fever virus, lymphocytic choriomeningitis virus and other arenaviruses; upper
and lower respiratory infections, serious acute respiratory tract illness and
pneumonia associated with influenza A, B, and C; measles, mumps, and
25 parainfluenza, associated with paramyxoviruses; enteric, neuromuscular and central
nervous system infections associated with picornaviruses; acquired immune

- 38 -

5 deficiency syndrome (AIDS) and associated infections and clinical syndromes
associated with HIV infection; and encephalitis and measles associated with
togaviruses.

Moreover, given the functional similarities of the compounds of the present invention and other RNA binding molecules, *e.g.*, neomycin, erythromycin
10 and aminoglycosides, the compounds and compositions of the present invention can be used as antibiotic therapies. Antibiotics are used in the treatment of infectious diseases in plants, animals and man, and may kill and/or inhibit the growth of microorganisms. Therefore, the compounds and compositions of the present invention may be used as bacteriocidal, bacteriostatic and broad-spectrum antibiotic
15 agents.

Pharmaceutical Formulations

The compositions of the present invention can be administered in dosages and by techniques well known to those skilled in the medical, veterinary,
20 and agricultural arts taking into consideration such factors as the age, sex, weight, species and condition of the particular patient, and the route of administration. The compositions of the present invention can be administered alone, or can be co-administered or sequentially administered with additional, non-triazine based antiviral agents, such as, *e.g.*, Acyclovir, α -interferon, ribavirin, and various
25 protease inhibitors, *e.g.*, ritonavir, indinavir, saquinavir, and/or additional non-

- 39 -

5 triazine based antibiotics, such as, *e.g.*, erythromycin, gentamycin, nanamycin, and streptomycin.

The effect of simultaneous administration of triazine compound 5 and 2'-deoxy-3'-thiacytidine, a well known nucleoside analog having antiviral activity, was examined in order to assess the interaction between the two therapies. The 10 results show a strong synergistic interaction when the two drugs are administered together at a 1:15 molar ratio (3TC: triazine; Figure 4A). The antiviral activity observed with the combination drug treatment is larger than the additive activity expected based on the activities of each compound administered alone. A synergistic response allows the use of lower amounts of each drug in combination 15 therapies, which reduces the toxicity and secondary risks. Moreover, combination therapies with drugs acting on different targets should reduce the probability that drug resistant viral strains will develop.

Moreover, the formulations of the present invention can be administered in a formulation suitable for the manner of administration, including 20 but not limited to liquid preparations for mucosal administration, *e.g.*, oral, nasal, anal, vaginal, peroral, intragastric administration and the like, such as solutions, suspensions, syrups, elixirs. Further, liquid preparations for administration of the compositions of the present invention for parenteral, subcutaneous, intradermal, intramuscular, intravenous administrations, and the like, such as sterile solutions, 25 suspensions or emulsions, *e.g.*, for administration by injection, can be formulated without undue experimentation. Oral administration is presently preferred.

- 40 -

5 In order for a composition to be administered to an animal or human, and for any particular method of administration, it is preferred to determine the toxicity, such as by determining the lethal dose (LD) and LD₅₀ in a suitable animal model, *e.g.*, mouse; the dosage of the composition(s), and the concentration of components in the composition; and the timing of administration in order to
10 maximize the antiviral and/or antimicrobial response. Such factors can be determined without undue experimentation by such methods as titrations and analysis of sera for antibodies or antigens, *e.g.*, by ELISA and/or EFFIT analysis. Such determinations do not require undue experimentation from the knowledge of the skilled artisan, the present disclosure and the documents cited herein.

15 The formulations can be administered in a pharmaceutically effective amount, an antiviral effective amount and/or in an antimicrobial effective amount, taking into account such factors as the relative activity and toxicity for the target indication, *e.g.*, antiviral activity and/or antimicrobial activity, as well as the route of administration, and the age, sex, weight, species and condition of the particular
20 patient.

 The compositions of the present invention can be solutions, suspensions, emulsions, syrups, elixirs, capsules, tablets, and the like. The compositions may contain a suitable carrier, diluent, or excipient, such as sterile water, physiological saline, glucose, or the like. Moreover, the compositions can also be lyophilized, and/or may contain auxiliary substances, such as wetting or
25 emulsifying agents, pH buffering agents, adjuvants, gelling or viscosity enhancing

- 41 -

5 additives, preservatives, flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired. Standard texts, such as "Remington's Pharmaceutical Science", 17th Ed., 1985, incorporated herein by reference, may be consulted to prepare suitable preparations, without undue experimentation.

10 Suitable dosages for compositions of the present invention can be determined without undue experimentation based upon the Examples provided below, and the documents cited herein. For instance, suitable dosages of antiviral and/or antibiotic agent in a composition can be 0.1 to 250 mg/kg/day, preferably below 100 mg/kg/day, and most preferably below 50 mg/kg/day.

15 In a further embodiment, the compounds of the present invention can be used as lead compounds to improve the antiviral and/or antibiotic activities of the compounds. This can be done by modifying certain functional groups of the compounds of the present invention based upon a recognition of the structure/activity relationship between a particular functional group in a compound 20 and its biological activity. Such modifications include synthetic manipulation of the size, hydrophilicity, hydrophobicity, acidity and basicity of a functional group, which may inhibit or enhance the activity of a compound.

25 Moreover, based upon the observed binding interaction between the compounds of the present invention and nucleic acids, the compounds of the present invention can be used in a method of detecting and/or purification of nucleic acids, e.g. binding assays and affinity chromatography. For example, the compounds of

- 42 -

5 the invention can be covalently attached to a chromatographic support and a nucleic acid-containing solution can be eluted over the solid support, which will bind the target nucleic acid as the other components of the solution elute from the column in the flow-through. With regard to binding assays and affinity chromatography, reference is made to A. Fersht, Enzyme Structure and Mechanism, 2d Ed., W.H. Freeman & Co., New York, 1985, and R.K. Scopes, Protein Purification, Principles and Practice, 2d Ed., Springer-Verlag, New York, 1987, the disclosures of which are hereby incorporated herein by reference.

10 Additionally, the compounds of the present invention could be used as inhibitors of specific steps of the viral replication cycle in order to study the process *in vivo* or *in vitro*. In a diagnostic application, the compound could be used 15 for detection of specific RNA species in samples by using a triazine derivative labeled with a fluorescent, immunochemical, or radioactive moiety. Further, such labeled triazine compounds could be used to study intracellular localization of the RNA target by electron-microscopy or light microscopy using tissue culture 20 preparations.

The following examples are intended to further illustrate the invention without imposing any undue limitations thereon.

25 **Example 1: HIGH-THROUGHPUT IDENTIFICATION OF ϵ RNA LIGANDS**

Compounds of the invention were obtained from commercial sources. Compound 32 is available from MicroSource Discovery Systems, Inc.,

- 43 -

5 Gaylordsville, Connecticut; compounds 64, 136, and 148 are available from
ComGenex, Inc., Budapest, Hungary; compounds 103 and 123 are available from
ChemBridge Corp., San Diego, California; and the remaining compounds are
available from Specs and Biospecs B.V., Rijswijk, The Netherlands.

The high throughput assays were performed in 96-well plates
10 containing eighty drugs (5 μ l, 60 μ g/ml in DMSO) distributed one per well in
columns 2-6 and 8-12 of the 8 x 12 96-well array. The remaining 16 wells in
columns 1 and 7 were filled with 5 μ l DMSO to serve as the control reactions. 45
 μ l of reaction mixture containing buffer, salts and radiolabeled target RNA were
delivered on each well of the compound-containing plates to yield a 50 μ l mixture
15 containing 50 mM Tris-HCl, pH 7.5, 200 mM KCl, 5 mM MgCl₂, 5 mM DTT, 6
 μ g/ml test compound, and 25 nM [³²P]-labeled cRNA. The reaction was started by
addition of the biotinylated oligonucleotide, 262.104 A (5 μ l) to a final
concentration of 100 nM. The reaction was incubated at 25 °C for 60 minutes, and
then 5 μ l of 0.3 mg/ml SAAP (streptavidin alkaline phosphatase conjugate, Pierce,
20 Rockford, Ill.) was added. The reaction was incubated for an additional 30 minutes
at 25°C and filtered through 96-well format HATF nitrocellulose filters (Millipore,
Bedford, MA) using a multiscreen vacuum manifold (Millipore, Bedford, MA).
Subsequently, 300 μ l of wash buffer (50 mM Tris-HCl, pH 7.5, 200 mM KCl) was
filtered through to wash the filters. The filters were dried and supplemented with
25 20 μ l scintillation fluid (Super Mix, Wallac Oy, Turku, Finland). The amount of

- 44 -

5 hybrids formed was determined by scintillation counting of the radiolabeled ϵ RNA retained on the filters.

The inhibitory effect of a test compound (expressed as percentage of inhibition, % Inh.) was calculated using the following formula:

$$\% \text{ Inh.} = (1 - (Rx/Ro)) \times 100$$

10 where Ro is the average retention of hybrids in the 16 identical control reactions in columns 1 and 7 and Rx is the hybrids retained in the presence of a test drug, x.

Biotinylated oligonucleotides 262.104 A (5'-biotin-TTA GGC ACA GCT TGG AGG CTT GAA CAG TG-3') and 208.92 A (5'-biotin-CGT CAT TGA CGC TGC GCC CA-3') were synthetically prepared (Oligos Etc., Willsonville, OR). These oligonucleotides are complementary to regions of the ϵ RNA and RRE RNA targets, respectively.

A plasmid containing the target sequence following the bacteriophage SP6 promoter was used as a template for the synthesis of radiolabeled ϵ RNA using [α^{32} P]-UTP and SP6 RNA polymerase as described by the suppliers, e.g., Ambion, Austin, TX, and by methods well known to those of ordinary skill in the art.

20 Compounds that inhibited the primary screening assay described above were individually titrated in the same assay at concentrations between 0.1 μ M and 200 μ M in the absence and presence of 60-fold excess rRNA as a non-specific competitor. A third titration was performed in a heterologous assay using 25 radiolabeled RRE RNA as the target and the complementary biotinylated

- 45 -

5 oligonucleotide 208.92 A. From these three assays, the IC₅₀ values and specificity for each compound was calculated.

Results:

IC₅₀ values using rRNA competitor (from Example 1) and radiolabeled RRE RNA are shown in Table 1 for the following ligands. A compound is considered inactive if the titration course does not result in sufficient inhibition to estimate an IC₅₀ value. Specificity is calculated as the ratio of RRE + rRNA IC₅₀/εRNA + rRNA IC₅₀. When an εRNA ligand was inactive in the RRE assay the specificity of the ligand is defined as maximal (max) since a value cannot be calculated.

Table 1. IC₅₀ Values for 1,3,5-Triazine Compounds

<u>Compound</u>	<u>Specificity</u>	<u>HBV+ rRNA</u>	<u>RRE + rRNA</u>
		<u>IC₅₀ (μM)</u>	<u>IC₅₀ (μM)</u>
1	max.	32.4	inactive
2	max.	3.2	inactive
3	max.	66.9	inactive
4	max.	16.3	inactive
5	max.	49.3	inactive
6	max.	10.4	inactive
7	max.	2.4	Inactive
8	max.	4	inactive

- 46 -

	<u>Compound</u>	<u>Specificity</u>	<u>HBV+ rRNA</u>	<u>RRE + rRNA</u>
			<u>IC₅₀ (μM)</u>	<u>IC₅₀ (μM)</u>
5	9	132.6	6.2	inactive
	10	max.	12	inactive
	11	max.	15	inactive
	12	max.	2.6	inactive
	13	max.	4.9	inactive
10	14	max.	7.1	inactive
	15	max.	11	inactive
	16	max.	12.1	inactive
	17	max.	15.1	inactive
	18	max.	5.1	inactive
15	19	max.	9.9	inactive
	20	max.	11.7	inactive
	21	max.	14.4	inactive
	22	max.	3.6	inactive
	23	max.	5.7	inactive
20	24	max.	10	inactive
	25	max.	11.9	inactive
	26	max.	15	inactive
	27	max.	15.5	inactive
	28	max.	18.9	inactive
25	29	max.	24.8	inactive
	30	max.	25	inactive
	31	max.	30	inactive
	32	max.	32.6	inactive

- 47 -

	<u>Compound</u>	<u>Specificity</u>	<u>HBV+ rRNA</u>	<u>RRE + rRNA</u>
			<u>IC₅₀ (μM)</u>	<u>IC₅₀ (μM)</u>
5	33	max.	37.2	inactive
	34	max.	21	inactive
	35	max.	24.9	inactive
	36	53.8	28.9	1553.8
	37	max.	30.1	inactive
	38	max.	34.9	inactive
10	39	max.	39.9	inactive
	40	max.	21.9	inactive
	41	max.	24.9	inactive
	42	max.	30	inactive
	43	max.	30.1	inactive
	44	max.	35	inactive
15	45	max.	39.9	inactive
	46	max.	23.1	inactive
	47	max.	25	inactive
	48	max.	30	inactive
	49	max.	35	inactive
	50	max.	39.9	inactive
20	51	max.	39.9	inactive
	52	max.	66	inactive
	53	max.	70.1	inactive
	54	max.	89.9	inactive
	55	max.	100.1	inactive
	56	max.	42.1	inactive

- 48 -

	<u>Compound</u>	<u>Specificity</u>	<u>HBV+ rRNA</u>	<u>RRE + rRNA</u>
			<u>IC₅₀ (μM)</u>	<u>IC₅₀ (μM)</u>
5	57	max.	50.1	inactive
	58	max.	200.4	inactive
	59	max.	90.1	inactive
	60	max.	100.1	inactive
	61	max.	42.6	inactive
10	62	max.	54.3	inactive
	63	max.	69	inactive
	64	max.	71.9	inactive
	65	max.	99.9	inactive
	66	max.	113.5	inactive
15	67	max.	47.7	inactive
	68	max.	33	inactive
	69	max.	70	inactive
	70	max.	80.6	inactive
	71	max.	99.9	inactive
20	72	max.	119.9	inactive
	73	max.	120	inactive
	74	max.	125.9	inactive
	75	max.	160.1	inactive
	76	max.	200	inactive
25	77	max.	120	inactive
	78	max.	133.2	inactive
	79	max.	168.9	inactive
	80	max.	200	inactive

- 49 -

	<u>Compound</u>	<u>Specificity</u>	<u>HBV+ rRNA</u>	<u>RRE + rRNA</u>
			<u>IC₅₀ (μM)</u>	<u>IC₅₀ (μM)</u>
5	81	max.	120.1	inactive
	82	max.	149.9	inactive
	83	max.	184.7	inactive
	84	max.	120.1	inactive
	85	max.	53.8	inactive
10	86	max.	200	inactive
	87	37.0	8.1	300.1
	88	80.2	11.7	937.8
	89	6.0	12.5	75.3
	90	3.0	15	44.9
15	91	46.8	17.1	800
	92	4.0	2.5	10.1
	93	max	12.7	Inactive
	94	20.8	12	249.7
	95	2.8	13.7	39
20	96	5.0	15	75
	97	22.2	17.8	394.8
	98	2.7	3	8.1
	99	max	11.5	inactive
	100	49.6	12.1	600
25	101	3.6	14	50.1
	102	3.0	15.1	45.1
	103	10.0	20	200.1
	104	15.1	5	74.9

- 50 -

	<u>Compound</u>	<u>Specificity</u>	<u>HBV+ rRNA</u>	<u>RRE + rRNA</u>
			<u>IC₅₀ (μM)</u>	<u>IC₅₀ (μM)</u>
5	105	8.1	9.9	80.1
	106	5.8	12.1	70.1
	107	1.7	14.9	25
	108	2.5	16.1	40
	109	1.8	20	35
10	110	4.0	20	79.9
	111	20.0	23	460.3
	112	30.0	25	750.6
	113	9.1	33.1	300
	114	5.5	40	220
15	115	1.7	75.1	130.1
	116	1.3	20	25.1
	117	max.	15.6	inactive
	118	2.0	25	50.1
	119	7.1	35	250.1
20	120	24.1	46	1109.1
	121	5.0	79.9	400.1
	122	14.9	20.1	300
	123	3.0	25	74.9
	124	10.0	29.9	300
25	125	28.5	35.1	1000
	126	8.3	60.1	500.5
	127	1.0	80	80
	128	4.5	22	99.9

- 51 -

	<u>Compound</u>	<u>Specificity</u>	HBV+ rRNA	RRE + rRNA
			<u>IC₅₀ (μM)</u>	<u>IC₅₀ (μM)</u>
5	129	4.8	25	120
	130	12.2	32.9	400
	131	1.0	36.7	36.7
	132	11.4	70.1	800
	133	1.0	99.9	99.9
10	134	2.0	100.1	200
	135	2.0	149.9	300.1
	136	5.0	203.4	1017.2
	137	1.0	400	400
	138	0.1	500	49.9
15	139	0.2	2094.3	400.2
	140	4.2	120	499.9
	141	1.3	165.4	214.5
	142	5.0	226	1129.9
	143	0.5	445.9	223
20	144	0.1	1000	99.9
	145	3.1	129.9	400
	146	6.1	196	1194.9
	147	1.0	299.9	299.9
	148	max.	496.9	inactive
25	149	0.4	1000.1	399.9
	150	4.7	149.9	700.8
	151	3.5	200.0	699.9
	152	0.5	299.9	150

- 52 -

	<u>Compound</u>	<u>Specificity</u>	<u>HBV+ rRNA</u>	<u>RRE + rRNA</u>
			<u>IC₅₀ (μM)</u>	<u>IC₅₀ (μM)</u>
5	153	1.0	499.9	499.9
	154	0.3	1180.6	300
	155	max.	25.5	inactive
	156	max.	22.8	inactive
	157	max.	2.9	inactive
10	158	max.	7.4	inactive
	159	max.	2.7	inactive
	160	44.2	9.5	420.2
	161	max.	36.1	inactive
	162	max.	11.7	inactive
15	163	max.	99	inactive
	164	max.	48	inactive
	165	max.	18.8	inactive
	166	max.	36.3	inactive
	167	max.	50.9	inactive
20	168	max.	19.7	inactive
	169	max.	15.4	inactive
	170	119.3	6.2	739.9
	171	max.	9.4	inactive
	172	max	69.2	inactive
25	173	max.	89	inactive
	174	201.1	5.6	1126.3
	175	max.	5.9	inactive

- 53 -

	<u>Compound</u>	<u>Specificity</u>	<u>HBV + rRNA</u>	<u>RRE + rRNA</u>
			<u>IC₅₀ (μM)</u>	<u>IC₅₀ (μM)</u>
5	176	166.5	6.8	1132.5
	177	max.	6.2	inactive
	178	max.	12.7	inactive
	179	max.	13.2	inactive
	180	max.	13.7	inactive
10	181	max.	60	inactive
	182	max.	70.4	inactive
	183	max.	47.8	inactive
	184	2.0	1.7	3.4
	185	max.	203.3	inactive
15	186	max.	88.4	inactive
	187	max.	61	inactive
	188	max.	54.9	inactive
	189		inactive	inactive
	190	max.	223.7	inactive
20	191	max.	87	inactive
	192	max.	235	inactive
	193	max.	28	inactive
	194	max.	34	inactive
	195	max.	28.2	inactive
25	196	max.	32.7	inactive
	197		inactive	inactive
	198	max.	14.8	inactive

- 54 -

	<u>Compound</u>	<u>Specificity</u>	<u>HBV+ rRNA</u>	<u>RRE + rRNA</u>
			<u>IC₅₀ (μM)</u>	<u>IC₅₀ (μM)</u>
5	199	max.	33.8	inactive
	200	max.	12.1	inactive
	201	max.	53	inactive
	202	max.	68	inactive
	203	85.6	15.6	1334.6
10	204	max.	18.4	inactive
	205	max.	19.1	inactive
	206	max.	12.4	inactive
	207	max.	35.9	inactive
	208	max.	38.2	inactive
15	209	max.	9.3	inactive
	210	max.	3.3	inactive
	211	20.2	5.5	111
	212	max.	23.1	inactive
	213	33.3	15.6	518.8
20	214	max.	42.6	inactive
	215	max.	50	inactive
	216	max.	9	inactive
	217	max.	8.1	inactive
	218	12.0	4.8	57.8
25	219		inactive	inactive
	220	33.3	27.6	918.5
	221	max.	402.8	inactive

- 55 -

	<u>Compound</u>	<u>Specificity</u>	<u>HBV+ rRNA</u>	<u>RRE + rRNA</u>
			<u>IC₅₀ (μM)</u>	<u>IC₅₀ (μM)</u>
5	222	max.	48	inactive
	223	max.	48.8	inactive
	224	max.	60.1	inactive
	225	max.	193.3	inactive
10	226	5.0	84.4	422
	227	max.	12.8	inactive
	228	max.	79.3	inactive
	229	max.	4.4	inactive
15	230	max.	20.9	inactive
	231	max.	195.4	inactive
	232	max.	45.5	inactive
	233	max.	22.9	inactive
20	234	max.	48.2	inactive
	235	max.	9.9	inactive
	236		inactive	inactive
	237	max.	51.6	inactive
25	238	max.	1071	inactive
	239	max.	22.8	inactive
	240		inactive	inactive
	241	max.	5.7	inactive
	242	2.5	54.2	135.6
	243	max.	86.7	inactive
	244		inactive	inactive

- 56 -

	<u>Compound</u>	<u>Specificity</u>	<u>HBV+ rRNA</u>	<u>RRE + rRNA</u>
			<u>IC₅₀ (μM)</u>	<u>IC₅₀ (μM)</u>
5	245	max.	8.1	inactive
	246	max.	5.6	inactive
	247	max.	6.7	inactive
	248		inactive	inactive
	249	max.	47.2	inactive
10	250		inactive	inactive
	251	max.	45	inactive
	252		inactive	inactive
	253	59.9	11	658.8
15	254	3.7	87.7	328.7

Example 2: DETERMINATION OF ANTIVIRAL ACTIVITY

i. **Materials and Methods**

The antiviral activity of the compounds of the present invention is measured by the methods described in Korba and Gering, Antiviral Res. 19: 55-70 (1992).

Whenever possible, all materials were prepared sterile and solutions passed through 0.22 micron filters.

- 57 -

5

Materials

1. HBV hybridization probe: A 3.2kb full genome length HBV fragment was retrieved from a restriction digest of a plasmid clone (*e.g.*, pAM6) electrophoresed in a 1% agarose gel, isolated, and stored at -20 °C.
- 10 2. HBV gel standard: 1.0 μ l HBV standards (100 ng/ml) plus 5 μ l tracking dye and 14 μ l TE (per lane). HBV standards were made by performing separate *Bam H*I and *Eco R*I digests of cloned HBV DNA. The digests were combined in equimolar amounts and stored at -20 °C. This produced several HBV fragment (positive hybridization controls) as well as non-HBV plasmid DNA fragments (negative hybridization control). For example, pAM6 produces HBV DNA fragments of 3.2, 1.85, and 1.35kb, as well as a plasmid fragment of 4.3kb. This mixture served as a positive and a negative hybridization control, a size standard, and a quantitation standard that occupied only one lane of a gel.
- 20 3. HBV media standards: Culture medium (RP2) was collected from confluent non-G418 treated 2.2.15 cells and stored frozen at -70 °C. Aliquots were pooled as necessary (typically 1-2 liters) and centrifuged at 7000xg, 10 minutes to remove cellular debris. The supernatant was added to an Amicon Inc. "stirred cell" (8400 series) fitted with a YM100 membrane (cat. No. 13642) 400 ml, and ultrafiltered at approximately 20psi nitrogen with

- 58 -

5 constant stirring, at 4 °C (approximately 3-5 hours), to insure that the membrane was not allowed to dry. This resulted in approximately a 40-fold concentration by volume. HBV DNA content in the concentrated sample was quantitated by blot hybridization against a known standard quantity of HBV DNA. Approximately a 2-fold loss of HBV DNA (as compared to the theoretical starting concentration) frequently occurred during this process.

10 The final product was diluted to a standard concentration of 10ng HBV DNA/ml with RPMI 1640 (without FBS). The concentration was then rechecked by blot hybridization. The adjusted standard pool was again rechecked by blot hybridization. The adjusted standard pool was stored at -

15 70 °C in 5ml aliquots in screw-capped tubes and stable for at least 5 years.

ii. Guidelines for the Culture of 2.2.15 Cells

Cell cultures were handled aseptically, without antibiotics, and in contained facilities (BS level II). The basal culture medium used for the culture of 20 2.2.15 cells was RPMI 1640. Fetal Bovine Serum (FBS) was added at either 2% or 4% final concentration, and was not heat inactivated or lot tested. L-Glutamine was added to a final concentration of 4 mM. Complete culture medium was stored at 4 °C for up to 4 weeks. Cells were grown and maintained at 37 °C in a 5% CO₂ humidified atmosphere.

25 Flasks and plates were routinely seeded at a density of 3-5 x 10⁴ cells/cm². This seeding density produced confluent cultures in 3-5 days. Seeding

- 59 -

5 densities of approximately 1×10^4 cells/cm² were permissible and prolonged time to confluence. At confluence, cells were at a density of $3-5 \times 10^5$ cells/cm² and produced their maximal and relatively stable levels of HBV. A confluent, "healthy" T-75 flask, grown in medium with 4% FBS was subcultured in up to 6, 96-well or 24-well flat bottom plates.

10

iii. **"Primary" or "Screening" Assay (96-well plate format)**

15

This assay format is well suited to the screening of test compounds for potential antiviral activity. The assay provides a threshold assessment of antiviral activity by measuring (i) the levels of HBV virion release from the cells and (ii) cytotoxicity. Two rows of cells were used for each compound, and 4 rows for the assay controls (two for untreated, and two for positive antiviral control, e.g., 3TC). After incubating in the presence of test compound for 9 days, the media were harvested, transferred to 96-well U-bottom plates, and centrifuged. The supernatants were transferred to tubes for dot blot hybridization analysis of HBV virion DNA. The medium was aspirated off of the toxicity plates and discarded. Toxicity plates were then incubated with neutral red dye (MTT can also be used if preferred), washed with DPBS, developed with an acetic acid-ethanol solution, and assayed in a plate reader.

20

There are many options as to what concentration ranges to use for these assays. The compounds of the present invention were tested for toxicity at as high a concentration as the compound's solubility and the toxicity of the diluent

25

- 60 -

5 (frequently DMSO) allowed. The 2.2.15 cells will tolerate 2-3% DMSO for up to
10 days with little loss of viability.

- 10 1. 2.2.15 cells were seeded into 96-well, flat bottom tissue culture plates as described above. Duplicate plates were used for the antiviral treatments for each test compound (up to 8 compounds per pair of plates); after three to four days, cells were confluent and medium was yellow in color; the medium was removed and replaced with 100 μ l RP2 24 hours before the beginning of drug treatment.
- 15 2a. Compounds were prepared for antiviral treatment as follows:
- i) For each compound, a total of 4 concentrations were examined; this required 9 sets of 4 sterile, 1.1 ml minitubes (36 tubes per compound). Into the first tube of each set, sufficient compound was aliquoted to make up 700 μ l (for 10-fold dilution series) or 980 μ l (for 3.3-fold dilution series) of the highest test concentration; the other tubes were left empty.
- 20 ii) The sample aliquots for the last day of treatment were set up at a 3 fold higher concentration relative to the other aliquots; this was done to provide sufficient material for DNA analysis (see below).
- 25 iii) The tubes were covered with the rack lids, labelled appropriately, and stored at -20 °C or the appropriate temperature for the test compounds; this procedure prevents

- 61 -

5

multiple freeze-thaw cycles of stock solutions of the test compound, and ensures that all 9 daily test aliquots are treated in an identical manner with respect to temperature variations. If compounds were stored at 4 °C, the tops of the tubes were covered with a sheet of parafilm to prevent evaporation.

10

2b. Compounds were prepared for toxicity treatment as follows:

For each compound, a total of 4 concentrations were examined. This required 9 sets of 4 sterile, 1.1 ml minitubes (36 tubes per compound). Into the first tube of each set, sufficient compound was aliquoted to make up 465 μ l of the highest test concentration. The other tubes were left empty. The tubes were covered with the rack lids, and stored at -20 °C or at an appropriate temperature. Tubes for the last day of treatment for toxicity testing contain the same amount of compound as used the previous days (not 3xas for the antiviral assays).

15

20

3a. The compound dilution series was prepared for antiviral treatment as follows:

i) For a 10-fold dilution series: to the first (compound containing) tube was added 700 μ l (175 μ l x 4). 630 μ l (210 μ l x 3) RP2 culture medium was added to the remaining 3 tubes.

25

The first tube was mixed by pipeting up and down with a pipetman (a multichannel pipetman permits the simultaneous

- 62 -

5

processing of multiple compounds). 70 μ l of test compound-containing medium were serially transferred from the first tube to the other 3 tubes, taking care to thoroughly mix each tube before transferring medium;

10

ii) For a 3.3-fold dilution series: 960 μ l (160 μ l x 6) of RP2 was added to the first tube (containing the aliquot of compound) and 640 μ l (160 μ l x 4) RP2 was added to each of the empty tubes. 280 μ l of test compound-containing medium were serially transferred from the first tube to the other 3 tubes.

15

3b. The cytotoxicity of test compounds was analyzed in a 3.3-fold dilution series as follows. 485 μ l (155 μ l x 3) of RP2 were added to the first tube (containing the aliquot of compound) and 310 μ L (155 μ l x 2) RP2 to each of the 3 remaining tubes. 150 μ l of test compound-containing medium were serially transferred from the first tube to the other 3 tubes.

20

4. Treatments were initiated by the following procedure:

25

a) The culture medium was removed with care to minimize the time that the cell monolayers are without medium;

b) 100 μ l of each dilution of every compound was added to each of 6 wells (3 wells per plate) using the configuration listed below as an example. The lowest concentration was added

- 63 -

5

first, and the same tips were used to add the higher concentrations. The untreated cells received 100 μ l RP2 per well (untreated cells have to be carried on only one pair of the antiviral assay plates).

10

Col. 1 -3 Col.4-6 Col.7-9 Col. 10-12

Row A ----- untreated cells -----

Row B drug 1 @ 1X drug 1 @ 1/10X drug 1 @ 1/100X drug 1 @
/1000X

Row C drug 2 @ 1X

15

Row D

Row E

Row F

Row G

Row H

drug 7 @1/1000

20

c) Treatments were repeated daily for 9 days. For the last day of treatment, and additional 200 μ l RP2 were added to each well of the antiviral assay plates after the wells are treated with the test compounds (a total of 300 μ l medium per well).

25

- 64 -

- 5 5. A single plate was used for the toxicity treatments for each test compound (up to 7 compounds per plates since the top row were reserved for untreated cells on every toxicity plate). To initiate the treatments, the culture medium was removed, and 100 μ l of each dilution of every compound were added to each of 3 wells using a configuration similar to that shown above for the antiviral treatments.
- 10 The untreated cells received 100 μ l RP2 per well. Treatment was repeated daily for 9 days.
- 15 6. The assay was terminated and samples harvested for quantitative analysis of HBV virion DNA, by removing the culture medium 24 hours following the 9th day of treatment and storing the culture medium in 96-well U-bottom culture plates. These samples were stored at 4 °C until blotting was performed. Samples were eventually be transferred to -20 °C for long term storage.

20 iv. Assay for Effects on Intracellular HBV Replication (24-well plate format)

This assay format serves to further define the action of potential antiviral agents by permitting an assessment of the levels of intracellular HBV DNA replicative forms. This type of assay is usually performed on compounds identified as active in the 96-well plate format since the effective antiviral concentrations observed in those experiments can be used as a guide for this type of assay (which is considerably more labor intensive and costly). In general, a 3- to 5-fold higher

- 65 -

5 concentration of compound will be needed than that observed in the antiviral assay
to produce similar levels of effects on intracellular HBV DNA replication. 2.2.15
cells are seeded in 24-well plates for this assay and treated with test compounds for
9 days. The medium is collected at the end of the treatment period for analysis of
HBV virion DNA. For analysis of intracellular HBV DNA, the monolayers are
10 lysed with guanidine thiocyanate/sarcosyl/βME, dialyzed, digested with
SDS/Proteinase K, extracted with phenol and chloroform, and precipitated with
sodium acetate/isopropanol. The intracellular DNAs are then resuspended, digested
with *Hind* III, subjected to gel electrophoresis, and transferred to nitrocellulose for
hybridization analysis.

- 15 1. 24-well culture plates are seeded as described above. The day before
the addition of compounds, the medium is changed to RP2 (0.5 ml
per well). As in the 96-well plate assay, duplicate plates are used. A
total of 2 wells on each plate are treated with each dilution of
compound (4 wells per dilution).
- 20 2. Compounds are prepared for antiviral treatment as follows:
For each compound, a total of 4 concentrations are examined. This
requires 9 sets of 4 sterile, 1.1 ml minitubes (36 tubes per
compound). Into the first tube of each set, sufficient compound is
 aliquoted to make up 2.2ml of drug-containing medium (additional
medium to make up the proper total volume was added at the time of
25 cell treatment (see step 4 below). Tubes for the last day of treatment

- 66 -

- 5 for toxicity testing contain the same amount of compound as used the previous days (not 3X as for the 96-well plate assay). The tubes are covered with the rack lids, and stored at -20 °C or at an appropriate temperature.
- 10 3. Compounds in this assay are tested in a 3.3-fold dilution series. To make this dilution series, 720 μ l (240 μ l x 3) are added to the first tube. 460 μ l (230 μ l x 2) of medium are added to the remaining 3 tubes. 200 μ l are serially transferred from the first tube to the remaining 3 tubes.
- 15 4. Wells are treated from the lowest concentration of drug to the highest, adding 100 μ l to each of the 4 wells. An additional 400 μ l of RP2 (without drugs) are added to each well. Culture medium is continually changed and test compounds are added each day for a total of 9 days.
- 20 5. 24-hours following the final addition of compound, the culture medium is collected and stored in new 24-well plates. A 250 μ l aliquot of each stored culture medium sample is transferred to a 96-well U-bottomed culture plates (one plate can hold samples from up to 4, 24-well plates), and stored at 4 °C until dot blotting is performed.
- 25 6. The cell monolayers are then lysed for analysis of intracellular HBV DNA as described above.

- 67 -

5 vi. Neutral Red Dye Determination of Drug Toxicity

The antiviral effect of any compound was evaluated relative to its toxicity. Cells were seeded and treated following the guidelines above, after which a neutral red dye uptake assay was performed to assess toxicity as described below. Other assays of cytotoxicity (e.g., MTT) can be substituted for the procedure 10 described below. Note that this procedure assesses toxicity under culture and treatment conditions which are identical to those used for the antiviral analyses, thereby permitting a determination as to whether the reduction in virus production due to a specific antiviral effect or due to a cytotoxic effect on the host cell. Since the cultures, by necessity, are at confluence, the cytotoxic effects of the test 15 compounds will probably be reduced relative to the cytotoxic effects that would be expected for actively dividing cells.

1. Cultures were treated with test compounds on the designated toxicity plates as described above.
2. The culture medium was carefully removed 24 hours following the 20 9th day of treatment. The monolayer was fully removed in the top left three wells (row A, col. 1-3). These wells were used as "blanks" for the plate reader.
3. 100 μ l DPBS (containing 0.01% neutral red dye) were added to each well, including the empty wells, and Incubated in the tissue culture 25 incubator for 30 minutes.

- 68 -

5 4. The dye was removed carefully and gently, using a multichannel pipetman since the monolayers can become fragile after incubation with neutral red dye. 200 μ l DPBS were added to all the wells taking care not to displace the monolayers. The DPBS was removed and 100 μ l 50% EtOH/1% glacial acetic acid (in H₂O) were added to each well. The plates were mixed for 15 minutes on an orbital platform shaker (120-150 RPM) to allow for full extraction of the dye from the cells.

10 5. Optical absorbance at 510nm was read in an ELISA type plate reader, using the 3 empty wells to set the background. An average absorbance value was calculated for the 9 untreated cultures on a 15 plate, and the absorbance of dye for the treated cultures on the same plate was expressed as a percentage of that value. This procedure was repeated for each individual plate.

20 Table 2 shows the antiviral activity of a group of ϵ RNA ligands. The micromolar concentration at which the production of extra-cellular virus was reduced by 50% (EC₅₀) and was reduced by 90% (EC₉₀) is reported. Because HBV does not cause cell death, the cytotoxic potential of the compounds can also be estimated in the same cultures by measuring cell death by the neutral red uptake method, as described above. This value is expressed by 50% cell death (CC₅₀ μ M).

- 69 -

5

Table 2. Antiviral Activity of Selected 1,3,5-Triazine Compounds

Structure	<u>Antiviral</u> <u>EC₅₀ (μM)</u>	<u>Antiviral</u> <u>EC₉₀ (μM)</u>	<u>50% Cell Death</u> <u>CC₅₀ (μM)</u>
1	> 100	> 100	14
2	33	83	> 100
3	4.8	17	> 100
10	3.4	10	3.7
4	0.411	1.2	307
5	0.3	0.7	29
6	33	89	29
7	> 100	> 100	196
15	0.474	1.8	175
8	> 100	> 100	> 300
9	> 100	> 100	27
10	3.9	15	77
11	0.759	4.3	> 300
12	8.4	208	> 300
13	> 100	> 100	> 100
20	0.5	4	0.6
14	15	218	304
15	6.5	32	105
16	> 100	> 100	> 300
17	4.1	12	7.1
18	5.6	18	5.6
19	> 100	> 100	47
25	40	106	145
20	18	148	75
21	25	1	105
22			
23			
24			
25			

- 70 -

	<u>Structure</u>	<u>Antiviral EC₅₀ (µM)</u>	<u>Antiviral EC₉₀ (µM)</u>	<u>50% Cell Death CC₅₀ (µM)</u>
5	27	> 100	> 100	> 300
	28	> 100	> 100	33
	29	1.1	6.3	15
	30	54	199	230
	33	> 100	> 100	50
10	34	66	181	41
	35	2.3	17	3.9
	38	0.592	2.7	125
	39	1	17	5.3
	40	30	79	136
15	41	36	122	> 300
	42	6.1	22	237
	43	0.841	3.9	87
	44	4.8	20	285
	46	> 100	> 100	> 100
20	49	1.2	11	140
	50	29	70	30
	51	15	73	130
	52	4.5	24	11
	53	1.2	82.	72
25	56	> 100	> 100	63
	61	3.7	10	1.3
	62	> 100	> 100	> 100
	63	> 100	> 100	> 100
	65	> 100	> 100	17

- 71 -

	Structure	Antiviral <u>EC₅₀</u> (μM)	Antiviral <u>EC₉₀</u> (μM)	50% Cell Death <u>CC₅₀</u> (μM)
5	67	> 100	> 100	> 100
	68	> 100	> 100	> 300
	74	> 100	> 100	> 100
	85	> 100	> 100	209
10	88	4.8	14	> 100
	91	> 100	> 100	> 300
	93	0.006	0.503	54
	94	> 100	> 100	> 300
	97	> 100	> 100	49
15	99	52	162	157
	100	39	172	57
	113	> 100	> 100	> 300
	117	4.2	36	> 300
20	120	> 100	> 100	45
	125	3.9	11	265
	155	0.001	0.063	59
	156	4	13	359
25	157	0.71	2.9	59
	158	42	129	112
	159	0.498	1.9	101
	160	0.42	4.1	> 300
	161	0.55	6.8	> 300
	162	0.923	7.5	436
	163	0.958	7.6	150
	164	0.863	9.7	201

- 72 -

	Structure	Antiviral <u>EC₅₀</u> (μM)	Antiviral <u>EC₉₀</u> (μM)	50% Cell Death <u>CC₅₀</u> (μM)
5	165	3.8	11	> 300
	166	1.4	11	252
	167	1.7	12	161
	168	0.7	15	> 300
	169	2.5	37	> 300
10	170	4	40	499
	171	5	52	174
	172	5.2	64	> 300
	173	5	68	247
	174	5.5	72	133
15	175	5	75	> 300
	176	31	86	> 300
	177	5	90	> 300
	178	5	95	272
	179	26	123	> 300
20	180	12	131	> 300
	181	6	136	> 300
	182	54	191	> 300
	183	52	231	> 300
	184	13	111	441
25	185	12	107	> 300
	186	66	332	771
	187	7.1	116	266
	188	12	102	218
	189	2.5	60	88

- 73 -

Structure	Antiviral EC₅₀ (μM)	Antiviral EC₉₀ (μM)	50% Cell Death CC₅₀ (μM)
5 190	> 100	> 100	945
191	> 100	> 100	836
192	> 100	> 100	739
193	> 100	> 100	666
194	> 100	> 100	626
10 195	> 100	> 100	400
196	> 100	> 100	381
197	> 100	> 100	354
198	> 100	> 100	336
199	> 100	> 100	331
15 200	> 100	> 100	309
201	> 100	> 100	> 300
202	> 100	> 100	> 300
203	> 100	> 100	> 300
204	> 100	> 100	> 300
20 205	> 100	> 100	> 300
206	> 100	> 100	> 300
207	> 100	> 100	> 300
208	> 100	> 100	> 300
209	> 100	> 100	> 300
25 210	> 100	> 100	> 300
211	> 100	> 100	> 300
212	> 100	> 100	> 300
213	> 100	> 100	> 300
214	> 100	> 100	> 300

- 74 -

	Structure	Antiviral <u>EC₅₀</u> (μM)	Antiviral <u>EC₉₀</u> (μM)	50% Cell Death <u>CC₅₀</u> (μM)
5	215	> 100	> 100	> 300
	216	> 100	> 100	> 300
	217	> 100	> 100	> 300
	218	> 100	> 100	> 300
	219	> 100	> 100	> 300
10	220	> 100	> 100	> 300
	221	> 100	> 100	> 300
	222	> 100	> 100	> 300
	223	> 100	> 100	> 300
	224	> 100	> 100	> 300
15	225	> 100	> 100	281
	226	> 100	> 100	280
	227	> 100	> 100	247
	228	> 100	> 100	243
	229	> 100	> 100	237
20	230	> 100	> 100	231
	231	> 100	> 100	218
	232	> 100	> 100	190
	233	> 100	> 100	188
	234	> 100	> 100	188
25	235	> 100	> 100	178
	236	> 100	> 100	171
	237	> 100	> 100	163
	238	> 100	> 100	163
	239	> 100	> 100	154

- 75 -

	<u>Structure</u>	<u>Antiviral EC₅₀ (μM)</u>	<u>Antiviral EC₉₀ (μM)</u>	<u>50% Cell Death CC₅₀ (μM)</u>
5	240	> 100	> 100	154
	241	39	111	164
	242	40	117	172
	243	67	280	409
	244	34	103	143
	245	> 100	> 100	137
10	246	5.2	103	141
	247	> 100	> 100	136
	248	> 100	> 100	135
	249	> 100	> 100	134
	250	> 100	> 100	123
	251	> 100	> 100	96
15	252	9.5	85	61
	253	18	286	193
	254	> 100	> 100	58

20

25

The compounds show a potent antiviral activity. In particular, compounds 5 and 6 show antiviral activities with EC₉₀ values within 3 to 5-fold of that observed for 3TC (2'deoxy-3-thiacytidine), a well known antiviral drug, in the same assay. The figure ">" represents that no effect was observed at the highest concentration tested.

It is noted that the compounds tested above evidenced a wide range of antiviral activity, with some compounds demonstrating more activity than other

- 76 -

5 compounds. It is believed that all structures 1-254 may have activity against the HBV. However, as is understood by persons of ordinary skill in the art, assay results demonstrating inactivity may be due to a number of factors, such as cell permeability and metabolic stability.

10 **Example 3: Antiviral Combination Therapies**

Compound 5 and 3TC were tested at varying concentrations, alone and in combination, in the antiviral assay outlined in Example 2, above. The reduction in virus production when these drugs were tested independently is shown in Figure 3. 3TC alone causes 90% viral reduction (EC_{90}) at 216 nM, while compound 5 alone exhibits an EC_{90} at 1300 nM.

15 When compounds 5 and 3TC were tested in combination with molar ratios of 1:15, 1:5, and 1:1.5, the results are shown in Figures 4A, 4B, and 4C. The front row column of each plot shows the expected % viral reduction if the effects of each drug are additive. The back row in each plot shows the observed antiviral activity. The results show a strong synergistic effect when the drugs are mixed at a 1:15 (3TC:compound 5) molar ratio. For example, approximately 7% viral reduction is the expected additive effect of 20 nM 3TC and 300 nM compound 5, but the observed viral reduction reached 92%, which is indicative of a synergistic interaction.

- 77 -

5

These results suggest that when combined in a 1:15 ratio these two drugs could be used at approximately 4 to 10-fold lower concentrations than those needed when each drug is administered alone.

Example 4: Nucleic Acid Binding of Triazine Compounds

10

Reaction mixtures (10 μ l) containing 50 mM Tris-HCl, pH 7.5, 50 mM KCl, 0.5 mg/ml rRNA (as a carrier), 0.5 pmol of 3'-end 32 P-labeled ϵ RNA, 0.05 units of *B. Cereus* RNase, and compound 5 at concentrations between 0 and 200 μ M were incubated at 25 °C for 30 minutes. The reaction products were resolved by gel electrophoresis in polyacrylamide gels. *B. Cereus* nuclease is a single strand specific RNase. The results are shown in Figure 5A, wherein the sections of the ladder of digestion products corresponding to cleavage events occurring in the bulge and loop sections of the ϵ RNA structure. It is evident that increasing concentrations (indicated at top) of compound 5 in the reaction results in a decrease in cleavage at specific positions of the bulge indicated by stars.

15

Conversely, the loop and other regions of the structure where not affected. Similar results were obtained using compounds 6, 15, 28, 33, and 61.

20

These results indicate that the triazine compound bind RNA and that it does so at a site overlapping the bulge region. Moreover, an RNA containing a structural element similar to the bulge of ϵ RNA is likely to be bound by a triazine compound increasing the stability of the RNA structure.

25

- 78 -

5 Further, a smaller RNA target containing only the bulge region of εRNA was prepared, and the melting temperature (tm) of this RNA structure was determined by monitoring the change in optical density (OD) at 260 nm while increasing the temperature. A 1 ml aliquot of reaction mixture contained 50 mM NaCl, 10 mM sodium cacodylate, pH 7.0, 10% DMSO, and 2 μM bulge RNA.

10 The results are shown in Figure 6. The y-axis shows the first derivative of the change in OD at 260 nm in OD units/degree C. The reaction containing 2 μM RNA and no drug shows that the RNA has a tm of 65 °C, and upon addition of 10 μM compound 6, the tm is shifted to 83 °C. These results suggest that the RNA structure is stabilized by the ligand.


15 All patents, applications, test methods, and publications mentioned herein are hereby incorporated by reference.

Many variations of the present invention will suggest themselves to those skilled in the art in light of the above detailed disclosure. All such modifications are within the full extended scope of the appended claims.

- 79 -

5 What is claimed is:


1. A pharmaceutical formulation comprising a compound of formula IA:



or IB:

10

15



20

- 80 -

5

wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, non-aromatic heterocyclic, fused or polycyclic ring and aryloxy;

wherein said alkyl, alkenyl or alkynyl is optionally substituted

10 with one or more substituents selected from the group consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl, carboxyl, ester, amide, primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl, cycloalkenyl or alkynyl, and

15 wherein said aryl, aryloxy, heteroaryl, non-aromatic heterocyclic or fused or polycyclic ring is optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl, carboxyl, ester, amide, primary, secondary or tertiary amides, cyano, cycloalkyl, alkenyl, cycloalkenyl and alkynyl;

20 or wherein R¹ and R² together, R³ and R⁴ together, or R⁵ and R⁶ together, optionally form a cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, heteroaryl, or fused or polycyclic ring, said cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, heteroaryl, or fused or polycyclic ring optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl, carboxyl, ester,

- 81 -

5 amide, primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl,
cycloalkenyl and alkynyl;
or wherein R⁷ and R⁸ together optionally form a cycloalkyl,
cycloalkenyl, non-aromatic heterocyclic, or fused or polycyclic ring wherein said
cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, or fused or polycyclic ring are
optionally substituted with one or more substituents selected from the group
10 consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy,
amino, carbonyl, carboxyl, ester, amide, primary, secondary or tertiary amines,
cyano, cycloalkyl, alkenyl and alkynyl, with the proviso that when R⁷ and R⁸
together form a fused or polycyclic ring, the moiety of the fused or polycyclic ring
15 that binds with N is non-aromatic;
and pharmaceutically acceptable salts thereof;
and a pharmaceutically acceptable carrier or diluent.

2. The formulation of claim 1 comprising a compound of
20 formula IB wherein one R¹ or R² is an optionally substituted aryl.

3. For formulation of claim 1 comprising a compound of
formula IB wherein one of R⁷ or R⁸ is an optionally substituted aryl.

25 4. The formulation of claim 1, said formulation further
comprising at least one component selected from the group consisting of a diluent,


- 82 -

5 excipient, adjuvant, one or more non-triazine based antiviral or antibiotic agents, and mixtures thereof.


10 5. The formulation of claim 1, wherein said compound binds one or more nucleic acids.

15 6. The formulation of claim 5, wherein said one or more nucleic acids are RNA.

20 7. A method of preventing or treating hepatitis B virus infection in a patient in need of such treatment, said method comprising administering a compound of the formula IA:



or IB:



wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are each independently selected from the
10 group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, non-
aromatic heterocyclic, fused or polycyclic ring and aryloxy;

wherein said alkyl, alkenyl or alkynyl is optionally substituted
with one or more substituents selected from the group consisting of halogen,
hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl,
15 carboxyl, ester, amide, primary, secondary or tertiary amines, cyano, cycloalkyl,
alkenyl, cycloalkenyl or alkynyl, and

wherein said aryl, aryloxy, heteroaryl, non-aromatic
heterocyclic, or fused or polycyclic ring is optionally substituted by one or more
substituents selected from the group consisting of halogen, hydroxy, alkyl, nitro,
20 trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl, carboxyl, ester, amide,
primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl, cycloalkenyl and
alkynyl;

or wherein R¹ and R² together, R³ and R⁴ together, or R⁵ and R⁶
25 together, optionally form a cycloalkyl, cycloalkenyl, non-aromatic heterocyclic,
heteroaryl, or fused or polycyclic ring, said cycloalkyl, cycloalkenyl, non-aromatic
heterocyclic, heteroaryl, or fused or polycyclic ring optionally substituted with one

- 84 -

5 or more substituents selected from the group consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl, carboxyl, ester, amide, primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl, cycloalkenyl and alkynyl;

or wherein R⁷ and R⁸ together optionally form a cycloalkyl,
10 cycloalkenyl, non-aromatic heterocyclic, or fused or polycyclic ring wherein said cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, or fused or polycyclic ring are optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl, carboxyl, ester, amide, primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl and alkynyl, with the proviso that when R⁷ and R⁸ together form a fused or polycyclic ring, the moiety of the fused or polycyclic ring
15 that binds with N is non-aromatic;

and pharmaceutically acceptable salts thereof;
and a pharmaceutically acceptable carrier or diluent, wherein said
20 compound is administered in an amount and for a time sufficient to inhibit viral replication.

8. The method of claim 7, wherein said method comprises
administering a compound of formula IB wherein one of R¹ or R² is an optionally
25 substituted aryl.

- 85 -

5

9. The method of claim 7, wherein said method comprises

administering a compound of formula IB wherein one of R⁷ or R⁸ is an optionally substituted aryl.

10

10. The method of claim 7, further comprising administering at least one component selected from the group consisting of one or more additional nontriazine based antiviral agents, and mixtures thereof.

15


11. The method of claim 7, wherein said antiviral formulation is administered orally.

12. The method of claim 7, wherein said compound is administered at a dosage of 0.1 to 250 mg/Kg/day.

20

13. A method of preventing or treating microbial infection in a patient in need of such treatment, said method comprising administering a compound of the formula IA:

25




- 86 -

5

or IB:

10



wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 are each independently selected

15 from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, non-aromatic heterocyclic, fused or polycyclic ring and aryloxy;

wherein said alkyl, alkenyl or alkynyl is optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl, carboxyl, ester, amide,

20 primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl, cycloalkenyl or alkynyl, and

wherein said aryl, heteroaryl, non-aromatic heterocyclic or fused or polycyclic ring is optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy, 25 amino, carbonyl, carboxyl, ester, amide, primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl, cycloalkenyl and alkynyl;

- 87 -

- 5 or wherein R¹ and R² together, R³ and R⁴ together, or R⁵ and R⁶ together,
optionally form a cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, heteroaryl, or fused
or polycyclic ring, said cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, heteroaryl or
fused or polycyclic ring optionally substituted with one or more substituents selected from
the group consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy,
10 alkoxy, amino, carbonyl, carboxyl, ester, amide, primary, secondary or tertiary amines,
cyano, cycloalkyl, alkenyl, cycloalkenyl and alkynyl;

 or wherein R⁷ and R⁸ together optionally form a cycloalkyl, cycloalkenyl,
non-aromatic heterocyclic, or fused or polycyclic ring wherein said cycloalkyl,
cycloalkenyl, non-aromatic heterocyclic, or fused or polycyclic ring are optionally
15 substituted with one or more substituents selected from the group consisting of halogen,
hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl, carboxyl,
ester, amide, primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl and
alkynyl, with the proviso that when R⁷ and R⁸ together form a fused or polycyclic ring,
the moiety of the fused or polycyclic ring that binds with N is non-aromatic;

20 and pharmaceutically acceptable salts thereof;

 and a pharmaceutically acceptable carrier or diluent wherein said compound
is administered in an amount and for a time sufficient to inhibit viral replication.

14. The method of claim 13, wherein said method comprises
25 administering a compound of formula IB wherein one of R¹ or R² is an optionally
substituted aryl.

- 88 -

5 15. The method of claim 13, wherein said method comprises
administering a compound of formula IB wherein one of R⁷ or R⁸ is an optionally
substituted aryl.

10 16. The method of claim 13, wherein said compound is co-administered
with at least one component selected from the group consisting of one or more additional
non-triazine based antibiotic agents and mixtures thereof.

17. The method of claim 13 wherein said compound is administered
orally.

15

18. The method of claim 13 wherein said compound is administered at a
dosage of 0.1 to 250 mg/Kg/day.


- 89 -

5

19. A method of detecting a target nucleic acid comprising


(a) contacting the target nucleic acid with a compound of the formula IA:

10



or IB:

15



20

wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are each independently selected

from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, non-aromatic heterocyclic, fused or polycyclic ring and aryloxy;

wherein said alkyl, alkenyl or alkynyl is optionally substituted with

25 one or more substituents selected from the group consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl, carboxyl, ester, amide,

- 90 -

5 primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl, cycloalkenyl or alkynyl, and

wherein said aryl, aryloxy, heteroaryl, non-aromatic heterocyclic, or fused or polycyclic ring is optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy,

10 alkoxy, amino, carbonyl, carboxyl, ester, amide, primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl, cycloalkenyl and alkynyl;

or wherein R¹ and R² together, R³ and R⁴ together, or R⁵ and R⁶ together, optionally form a cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, heteroaryl, or fused or polycyclic ring, said cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, heteroaryl, or 15 fused or polycyclic ring optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, alkyl, nitro, trihalomethyl, aryl, aryloxy, alkoxy, amino, carbonyl, carboxyl, ester, amide, primary, secondary or tertiary amines, cyano, cycloalkyl, alkenyl, cycloalkenyl and alkynyl;

and pharmaceutically acceptable salts thereof;

20 and a pharmaceutically acceptable carrier or diluent; and

(b) monitoring an interaction between the target nucleic acid and at least one compound.

20. The method of claim 19, wherein said compound is labeled with a
25 moiety selected from the group consisting of a fluorescent compound, an antibody for the target nucleic acid, and a radioactive label.




FIG. 1




FIG. 2










FIG. 3

1/1/18

**FIG. 4****FIG. 5**

1/2/18

FIG. 7**FIG. 8****FIG. 9**

1/3/18




FIG. 10




FIG. 11







FIG. 12

1/4/18

FIG. 13**FIG. 14****FIG. 15**

SUBSTITUTE SHEET (RULE 26)

1/ 5/18




FIG. 16




FIG. 17




FIG. 18

1/6/18




FIG. 19




FIG. 20




FIG. 21

1/7/18




FIG. 22





FIG. 23

FIG. 24






FIG. 25




FIG. 26




FIG. 27

2/1/18




FIG. 28




FIG. 29







FIG. 30

2/2/18

FIG. 31**FIG. 32****FIG. 33**

2/3/18




FIG. 34




FIG. 35







FIG. 36




SUBSTITUTE SHEET (RULE 26)

2/4/18

FIG. 37**FIG. 38****FIG. 39**

SUBSTITUTE SHEET (RULE 26)

2/5/18

FIG. 40**FIG. 41****FIG. 42****SUBSTITUTE SHEET (RULE 26)**

2/6/18




FIG. 43




FIG. 44




FIG. 45

2/7/18




FIG. 46




FIG. 47







FIG. 48

**FIG. 49****FIG. 50****FIG. 51****SUBSTITUTE SHEET (RULE 26)**

3/1/18




FIG. 52




FIG. 53










FIG. 54

3/2/18

FIG. 55**FIG. 56****FIG. 57**

3/3/18

FIG. 58**FIG. 59****FIG. 60**

3/4/18




FIG. 61




FIG. 62




FIG. 63

3/5/18




FIG. 64




FIG. 65








FIG. 66

3/6/18

FIG. 67**FIG. 68****FIG. 69**

3/7/18




FIG. 70




FIG. 71




FIG. 72

SUBSTITUTE SHEET (RULE 26)




FIG. 73

FIG. 74





FIG. 75



4/1/18




FIG. 76




FIG. 77











FIG. 78

4/2/18

FIG. 79**FIG. 80****FIG. 81**

4/3/18

FIG. 82**FIG. 83****FIG. 84**

4/4/18




FIG. 85

FIG. 86





FIG. 87

4/5/18




FIG. 88




FIG. 89










FIG. 90




4/6/18

**FIG. 91****FIG. 92****FIG. 93**




4/7/18

FIG. 94**FIG. 95****FIG. 96**

SUBSTITUTE SHEET (RULE 26)

FIG. 97**FIG. 98****FIG. 99****SUBSTITUTE SHEET (RULE 26)**

5/1/18

FIG. 100**FIG. 101****FIG. 102**

5/2/18




FIG. 103

FIG. 104





FIG. 105



SUBSTITUTE SHEET (RULE 26)

5/3/18

FIG. 106




FIG. 107





FIG. 108



5/4/18




FIG. 109

FIG. 110








FIG. 111

5/5/18

FIG. III2**FIG. III3****FIG. III4**

5/6/18




FIG. 115




FIG. 116










FIG. 117

SUBSTITUTE SHEET (RULE 26)




5/7/18

FIG. 118**FIG. 119****FIG. 120**




6/18

FIG. 121**FIG. 122****FIG. 123****SUBSTITUTE SHEET (RULE 26)**




6/1/18

FIG. 124**FIG. 125****FIG. 126**




6/2/18

FIG. 127**FIG. 128****FIG. 129**

6/3/18

FIG. 130**FIG. 31****FIG. 132**

6/4/18

FIG. 133**FIG. 134****FIG. 135**

6/5/18




FIG. 136

FIG. 137








FIG. 138

6/6/18

FIG. 139**FIG. 140****FIG. 141**

6/7/18




FIG. 142




FIG. 143







FIG. 144

7/18

FIG. 145**FIG. 146****FIG. 147**

SUBSTITUTE SHEET (RULE 26)

7/1/18




FIG. 148




FIG. 149




FIG. 150

7/2/18




FIG. 151




FIG. 152








FIG. 153

7/3/18

FIG. 154**FIG. 155**

7/4/18

FIG. 156**FIG. 157**

7/5/18




FIG. 158




FIG. 159






FIG. 160

7/6/18

FIG. 161**FIG. 162**

7/7/18




FIG. 163




FIG. 164







FIG. 165

7/8/18

FIG. 166**FIG. 167****FIG. 168**




FIG. 169




FIG. 170




FIG. 171

8/1/18




FIG. 172




FIG. 173




FIG. 174

8/2/18




FIG. 175




FIG. 176










FIG. 177

8/3/18

FIG. 178**FIG. 179****FIG. 180**

SUBSTITUTE SHEET (RULE 26)

8/4/18

FIG. 181**FIG. 182****FIG. 183**

8/5/18




FIG. 184




FIG. 185










FIG. 186





8/6/18

FIG. 187**FIG. 188****FIG. 189**

8/7/18

FIG. 190**FIG. 191****FIG. 192**

9/18

FIG. 193**FIG. 194****FIG. 195****FIG. 196**

9/1/18




FIG. 197




FIG. 198




FIG. 199

9/2/18

FIG. 200




FIG. 201





FIG. 202



9/3/18




FIG. 203




FIG. 204




FIG. 205

9/4/18




FIG. 206




FIG. 207




FIG. 208

9/5/18




FIG. 209




FIG. 210







FIG. 211

9/6/18

FIG. 212**FIG. 213****FIG. 214**

10/18

FIG. 215




FIG. 216





FIG. 217



SUBSTITUTE SHEET (RULE 26)

10/1/18




FIG. 218

FIG. 219





FIG. 220



10/2/18

FIG. 221




FIG. 222











FIG. 223



10/3/18

FIG. 224**FIG. 225****FIG. 226**

10/4/18

FIG. 227**FIG. 228****FIG. 229**

10/5/18

FIG. 230




FIG. 231





FIG. 232



10/6/18

FIG. 233




FIG. 234





FIG. 235



10/7/18

FIG. 236




FIG. 237





FIG. 238



11/18

FIG. 239




FIG. 240





FIG. 241



11/1/18




FIG. 242

FIG. 243





FIG. 244

11/2/18

FIG. 245




FIG. 246





FIG. 247



SUBSTITUTE SHEET (RULE 26)

11/3/18




FIG. 248




FIG. 249




FIG. 250

11/4/18




FIG. 251




FIG. 252





FIG. 253

SUBSTITUTE SHEET (RULE 26)

12/18

FIG. 254

13/18




FIG. 255A**FIG. 255B****FIG. 255C**




FIG. 256


FIG. 257A

% Viral Reduction


15/1/18

FIG. 257B**SUBSTITUTE SHEET (RULE 26)**

16/18

FIG. 257C

17/18

FIG. 258A

17/1/18






FIG. 258B

18/18

FIG. 259A

18/1/18

FIG. 259B



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/00945

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D251/66 C07D251/70 A61K31/53 C07D403/12 C07D405/12
C07D409/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3 549 760 A (ALBERT JAMES R ET AL) 22 December 1970 see claim 1 ----	1
X	EP 0 240 854 A (HOECHST AG) 14 October 1987 see claim 1; examples ----	1
X	EP 0 092 479 A (ADIR) 26 October 1983 see claim 1; examples ----	1
X	WO 93 20056 A (JARMAN MICHAEL ;COLEY HELEN MARY (GB)) 14 October 1993 see claim 1; examples ----	1
	-/--	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the International search report

22 April 1999

06/05/1999

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

De Jong, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/00945

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 505 220 A (JARMAN MICHAEL ; WILMAN DERRY EDWARD VINCENT (GB); JUDSON IAN ROBER) 23 September 1992 see claim 1; examples ---	1
X	DE 29 30 039 A (AMERICAN CYANAMID CO) 21 February 1980 see claim 1 ---	1
X	EP 0 629 622 A (ZENYAKU KOGYO KK) 21 December 1994 see claim 1; examples ---	1
X	WO 93 10116 A (PFIZER) 27 May 1993 see claim 1; examples ---	1
X	H. BRUHIN ET AL: "Antituberculosis activity of some nitrofuran derivatives" J. PHARM. PHARMACOL., vol. 21, no. 7, 1969, pages 423-433, XP002100043 see tables ---	1
X	CHEMICAL ABSTRACTS, vol. 126, no. 12, 24 March 1997 Columbus, Ohio, US; abstract no. 152444, COLEY, HELEN M.: "N-(Hydroxymethyl) melamines" XP002100046 see abstract & GEN. PHARMACOL. (1997), 28(2), 177-182 ;ISSN: 0306-3623, 1997, ---	1
X	CHEMICAL ABSTRACTS, vol. 100, no. 9, 27 February 1984 Columbus, Ohio, US; abstract no. 61386, SU, YONGZHUANG ET AL: "Structure-activity relations of antitumor hexamethylmelamine derivatives" XP002100047 see abstract & ZHONGGUO YAOLI XUEBAO (1983), 4(4), 276-80 , 1983, ---	1
	-/-	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/00945

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 88, no. 17, 24 April 1978 Columbus, Ohio, US; abstract no. 115093, RUTTY, C. J. ET AL: "In vitro studies with hexamethylmelamine" XP002100048 see abstract & BIOCHEM. PHARMACOL. (1977), 26(24), 2385-91 ;ISSN: 0006-2952,1977, ---	1
X	MATSUNO, TOSHIYUKI ET AL: "Synthesis and aromatase-inhibitory activity of imidazolyl-1,3,5-triazine derivatives" CHEM. PHARM. BULL. (1997), 45(2), 291-296 CODEN: CPBTAL;ISSN: 0009-2363,1997, XP002100044 see table 1 ---	1
X	JARMAN, MICHAEL ET AL: "Synthesis and cytotoxicity of potential tumor-inhibitory analogs of trimelamol (2,4,6-tris'(hydroxymethyl)methylamino!-1, 3,5-triazine) having electron-withdrawing groups in place of methyl" J. MED. CHEM. (1993), 36(26), 4195-200 CODEN: JMCMAR;ISSN: 0022-2623,1993, XP002100045 see page 4195 - page 4196 ---	1
A	US 5 120 843 A (AYER DONALD E ET AL) 9 June 1992 see column 32, line 12; example 1 -----	1,7,13
A	EP 0 775 487 A (NIPPON SHINYAKU CO LTD) 28 May 1997 -----	1,7,13

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/00945

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 7-18

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 7-18

are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. Claims Nos.: not applicable

because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims Nos.: not applicable

In view of the extremely broad Markush claim 1, the search was executed with due regard to the PCT Search Guidelines (PCT/GL/2), C-III, paragraph 2.1, 2.3 read in conjunction with 3.7 and Rule 33.3 PCT, i.e. particular emphasis was put on the inventive concept, as illustrated by the examples. The international search was, in so far as possible and reasonable, complete in that it covered the entire subject-matter to which the claims are directed.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/00945

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 3549760	A	22-12-1970	NONE		
EP 0240854	A	14-10-1987	DE	3611427 A	08-10-1987
			AU	7105687 A	08-10-1987
			DK	171587 A	06-10-1987
			FI	871448 A	06-10-1987
			JP	62240673 A	21-10-1987
			PH	22967 A	10-02-1989
			PT	84618 A,B	01-05-1987
EP 0092479	A	26-10-1983	FR	2525597 A	28-10-1983
			AT	17724 T	15-02-1986
			AU	1381483 A	27-10-1983
			CA	1203803 A	29-04-1986
			JP	1432674 C	24-03-1988
			JP	58189168 A	04-11-1983
			JP	62040357 B	27-08-1987
			OA	7400 A	30-11-1984
			PT	76575 A,B	01-05-1983
			US	4514399 A	30-04-1985
			ZA	8302778 A	28-12-1983
WO 9320056	A	14-10-1993	AT	168105 T	15-07-1998
			AU	676677 B	20-03-1997
			AU	3894293 A	08-11-1993
			DE	69319590 D	13-08-1998
			DE	69319590 T	12-11-1998
			EP	0632805 A	11-01-1995
			ES	2118945 T	01-10-1998
			JP	7505380 T	15-06-1995
			US	5534625 A	09-07-1996
			US	5854244 A	29-12-1998
EP 0505220	A	23-09-1992	AU	1566792 A	21-10-1992
			CA	2106868 A	23-09-1992
			WO	9216513 A	01-10-1992
			JP	6511229 T	15-12-1994
			MX	9201258 A	01-10-1992
DE 2930039	A	21-02-1980	AU	528798 B	12-05-1983
			AU	4738879 A	07-02-1980
			BE	877950 A	28-01-1980
			CH	641959 A	30-03-1984
			PH	18639 A	23-08-1985
			ZA	7902562 A	27-08-1980
EP 0629622	A	21-12-1994	AU	3575193 A	13-09-1993
			DE	69322076 D	17-12-1998
			US	5489591 A	06-02-1996
			CA	2131004 A	02-09-1993
			WO	9317009 A	02-09-1993
WO 9310116	A	27-05-1993	AU	2599992 A	15-06-1993
			EP	0613477 A	07-09-1994
			FI	942188 A	11-05-1994
			HU	69722 A	28-09-1995
			JP	7506084 T	06-07-1995
			MX	9206468 A	01-05-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/00945

Patent document cited in search report	Publication date	Patent family member(s)		Publication date	
WO 9310116	A	NO PT US ZA	941785 A 101046 A 5536722 A 9208683 A	11-05-1994 28-02-1994 16-07-1996 11-05-1994	
US 5120843	A	09-06-1992	AU AU CA DK EP EP EP JP JP KR WO	624788 B 1709888 A 1338012 A 533589 A 0293078 A 0358676 A 0487510 A 7103118 B 2503198 T 9601920 B 8808424 A	25-06-1992 02-12-1988 30-01-1996 26-10-1989 30-11-1988 21-03-1990 27-05-1992 08-11-1995 04-10-1990 06-02-1996 03-11-1988
EP 0775487	A	28-05-1997	AU AU BR CA HU WO	703263 B 3192095 A 9508539 A 2197091 A 77735 A 9604914 A	25-03-1999 07-03-1996 28-10-1997 22-02-1996 28-07-1998 22-02-1996